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ABSTRACT
This Thesis describes a study of the antigenicity of the enzyme pig heart citrate 
synthase (PHCS).
A number of predictive methods based on the amino acid sequence (hydrophilicity 
and composite surface profile) and crystallographic structure (atomic mobility and 
protrusion) of PHCS were used to predict immunogenic peptides. These methods 
indicated that peptides at the region 288-302 (PCS-1) and the region 76-90 (PCS-2) 
should be important in the antigenic activity of PHCS. The selected peptides were 
synthesised by the Fmoc-solid phase method and used to produce anti-sera in rabbits.
Characterization of polyclonal and monoclonal antibodies originally raised against 
intact PHCS for their interaction with intact PHCS and the synthetic peptides, 
indicated that the polyclonal anti-serum contained antibodies reacting with native 
PHCS. The monoclonal antibody used showed reactivity with the enzyme in a 
denatured state. Monoclonal antibodies against PHCS were tested for their ability to 
bind to the synthetic peptide antigens PCS-1 and PCS-2. There was no evidence for 
specific binding of MAbs to either peptide in direct ELISA and soluble peptide did 
not inhibit the binding of MAb to intact PHCS. Furthermore, there was no evidence 
for specific binding of CNBr fragments of PHCS to an immunosorbent column 
containing immobilized MAb.
Anti-sera raised against the synthetic peptides showed a strict specificity for the 
immunizing peptide and both anti-peptide sera reacted with whole PHCS. However, a 
fraction of the antibody population in the anti-peptide sera was directed against 
denatured forms of the enzyme. Reactivity of anti-peptide sera with CNBr fragments 
of PHCS suggested that each antiserum reacts with the predicted fragment containing
(iv)
the corresponding sequence of amino acids to the immunizing peptide.
A correlation was observed between the results of the experimental study of 
antigenicity of PHCS and the predictive methods. This observation confirms the 
validity of the use of a predictive approach to identify potential synthetic peptide 
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21.1 INTRODUCTION
The key reaction of an immune response is the binding of antigen to antibody, 
whether it be on the surface of a B lymphocyte, or in the body fluid itself. In 
considering the response of the immune system to a "foreign" protein, a clear 
distinction must be made between its immunogenic and antigenic characteristics. 
Immunogenicity refers to the ability to induce an immune response and to produce 
specific antibodies, while antigenicity refers to the ability to react with an antibody. 
From these definitions, it is apparent that an immunogenic compound will also behave 
as an antigen while the converse is not necessarily true. However, some low molecular 
weight substances, such as drugs, hormones and other small molecules, are unable to 
induce a primary response and are thus non-immunogenic unless conjugated to larger 
"carrier" molecules; such substances are termed "haptens".
12  PROTEIN ANTIGENIC STRUCTURE
Proteins are composed of a number of distinct antigenic regions, called antigenic 
determinants or epitopes, which are the sites of an antigen which bind an antibody. 
These antigenic determinants can be either continuous (residing in the linear sequence 
of residues), or discontinuous (made up of residues that are not contiguous in sequence, 
but are brought together at the protein surface by the folding of the polypeptide 
chain) (Benjamin et al.. 1984; Atassi, 1978).
In this section, the discovery of different types of antigenic determinants will be 
described, using experiments employing serum antibodies.
Early workers used peptide fragments to study protein immunochemistry. As early 
as 1942, Landsteiner showed how peptides from silk fibroin were able to inhibit the 
reaction of the latter with its antibodies.
Work by Atassi and Collaborators from 1963-1975 (Atassi, 1975) led to the
3elucidation of the first complete antigenic structure of a protein, that of sperm whale 
myoglobin (swMb). They also determined the antigenic sites of hen egg lysozyme 
(Atassi, 1978), serum albumin (Atassi, 1982) and human adult haemoglobin (Hb) 
(Atassi, 1984).
The antigenic structure of a protein cannot be determined by the exclusive 
application of a single approach. A strategy was, therefore, developed (Atassi, 1975) 
which relied on five approaches. These are:
1) The study of the effect of conformational changes on the immunochemical 
behaviour of the protein.
2) The study of the immunochemistry and conformation of specific chemically 
modified derivatives of the protein.
3) The isolation and characterization of immunochemically reactive fragments that 
can account quantitatively for the total reaction of the native protein.
4) The study of the immunochemistry and conformation of specific chemical 
derivatives of immunochemically reactive peptides.
5) The synthesis, chemically, of the reactive regions defined by method 1 -4, and 
verification of the antigenic activity of these peptides.
Thus, determination of the antigenic structures of swMb and lysozyme has defined 
the problems involved in precise delineation of two types of antigen sites for 
subsequent workers studying protein antigenicity.
a) Main features of the antigenic structure of sperm whale myoglobin
Sperm whale myoglobin (swMb) is a protein of 153 amino acid residues, folded in 
a helical compact structure carrying 1 haem group (Edmundson, 1965).
Conformational changes in swMb caused by inclusion of modified haem groups, or 
modification of side chains, were shown to influence antigenic activity (Andres and 
Atassi 1970). A series of well purified derivatives, modified at a total of 23 amino
4acid sites, gave an initial indication of the location of some of the amino acids needed 
for antibody binding. However, care was needed to ensure that a resultant decrease in 
antibody binding following modification was directly due to the alteration of an 
essential antigenic site residue and not caused indirectly by a conformational change 
(Atassi, 1975; Atassi and Thomas, 1969). Spectroscopic measurement suggested that 
modification of peptides did not result in a change of their conformation in solution 
(Atassi and Perlstein, 1973).
Peptide fragments of swMb and derivatives of the same were tested for their 
ability to react with antisera raised against the native swMb (Atassi, 1975; Singhal and 
Atassi, 1971). Following this initial description of the epitopes, synthetic peptides 
corresponding to these regions were tested for their ability to inhibit 
immunoprecipitation of native swMb by antisera (Pai and Atassi, 1975; Koketsu and 
Atassi, 1974).
By this method native swMb was shown to have 5 major antigenic sites, each 
consisting of a linear amino acid sequence. This type of antigenic site is termed 
"continuous" (also termed a linear epitope). Two of the sites exhibit degrees of shift or 
displacement and minor variability in size (limited to ±1 residue only) from one 
antiserum to the next. The sites contain 6-7 residues and are between 19-23 A in their 
extended dimensions (Atassi, 1984). The size, surface locations and shape of these 
antigenic sites make them quite accessible for binding with antibody combining sites. 
Due to their content of hydrophilic residues (lysine, arginine, aspartate, glutamate and 
histidine), it was concluded that the interaction with antibodies must be predominantly 
polar in nature. Other stabilizing effects are contributed by hydroxy and non-polar 
amino acids through hydrogen bonding and hydrophobic interactions (Atassi, 1984).
The same five antigenic sites of swMb are recognised by rabbit, goat, chicken, cat, 
pig and mouse antisera (Twining et al„ 1980).
5b) Main features of the antigenic structure of lysozyme
Hen egg lysozyme is structurally quite different from myoglobin. It has 129 amino 
acid residues and it is held together in a tight conformation by 4 internal disulphide 
bonds. Lysozyme has only 25% of its residues forming a-helices (Imoto et al., 1972), 
compared to 70% for myoglobin (Singhal and Atassi, 1970).
Initial work using the previously proposed strategy proved difficult, partly due to 
the tight conformation making specific cleavage to fragments unreliable and partly due 
to the apparent need for the disulphide bonds to be intact in order to retain 
antigenicity (Lee and Atassi, 1973; Habeeb and Atassi, 1971a). This initial work 
predicted 3 antigenic sites.
Attempts were made to chemically synthesize regions corresponding to these sites 
and containing the disulphide bonds, but this proved too difficult for routine use 
(Atassi et al. 1975). Diglycyl segments, however, were found to be ideal replacements 
for disulphides in chemical-synthesis experiments. This newly developed concept of 
chemically synthesising a region where the constituent amino acids are not generally 
found sequentially linked by peptide bonds in the native protein was called "surface- 
simulation synthesis" (Atassi et al. 1976a).
For antigenic site 2, the initially implicated residues from chemical modification 
experiments are shown in Fig. 1.1a (Atassi et al., 1976b; Lee and Atassi, 1975). 
Following synthesis of a variety of peptides of the type shown in Fig. 1.1b, the final 
constituent residues of the antigenic site, Fig. 1.1c, were delineated (Atassi, 1978; Lee 
and Atassi, 1976). This was the first antigenic determinant shown to be comprised of 
surface residues in close proximity by virtue of the folding of the polypeptide chain, 
but which are not sequentially linked by peptide bonds. This type of epitope is called 
a discontinuous antigenic determinant (sometimes termed topographic).
All three major antigenic site of lysozyme are found to be discontinuous, they each 
contain 5-6 residues and are between 21-30X in their extended dimensions.
6Fig. 1.1 Antigenic structure o f Lysozyme
Fig. 1.1a
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la ) Shows the residues (ringed) thought to be im portant for the antigenicity of site 2 
of hen egg lysozyme following fragm entation work.
lb ) Shows the synthetic site found to carry the full reactivity o f site 2.
lc) Shows the constitutent residues of the native site 2 of hen egg lysozyme. T he 
distance (in nm) separating the constituent residues and the overall dimension of the 
site (in  its extend form ) are given, together w ith the dim ension o f the surface- 
sim ulation site (A tassi, 1978).
7c) Level of response to regions outside the major antigenic sites
The number of antibodies that can be bound by the delineated synthetic sites of 
each of the above proteins (swMb and lysozyme) accounts for the bulk of the total 
antibodies raised against the respective protein in a given antiserum (approximately 
98%). But, it should be noted that the regions outside the major antigenic sites are not 
entirely non-immunogenic, and that there is a very low level of antibody response 
(approximately 2%) versus these regions (Atassi, 1980; Atassi and Lee, 1978). Dean 
and Schechter (1979) found a subpopulation of less than 1% of total anti-Hb 
antibodies bound to an a l 29-141 epitope. This could only be detected when a large 
excess of antibody was used. Also, studies with synthetic reference non-antigenic 
regions of serum albumin revealed the presence of trace antibody binding accounting 
for 0.5-1.1% of the anti-protein antibodies in the antisera (Atassi, 1982; Sakata and 
Atassi, 1980).
d) Effects of amino acid substitutions and conformation on antigenic sites
The binding and recognition of a protein antigenic site was shown, during studies 
on the antigenic structure of myoglobin and lysozyme, to be highly dependent on the 
chemical characteristics of the residues constituting the site and on the conformational 
integrity of the site. Thus, alterations in the chemical nature of a side chain within a 
site (e.g. reversal or removal of a charge, creation of a new charge, elimination of a 
hydrogen bond) brought about either through chemical modification of a residue 
(Atassi et al., 1975, Atassi et al., 1973; Atassi and Thomas, 1969; Atassi, 1967) or its 
evolutionary replacement in a homologous protein, would cause a reduction or even 
complete elimination of the reactivity of the site (Atassi, 1978; Atassi, 1977; Atassi, 
1975).
8Conformational changes intentionally imposed on Mb and Hb by chemical 
alterations within the haem moiety (which resides outside the antigenic sites) lead in 
each protein to alterations in its antigenic reactivity (Atassi, 1967; Reichlin et al., 
1963). Also, lysozyme and a-lactalbumin, two highly homologous proteins, do not 
exhibit any immunochemical cross-reaction, presumably because of conformation 
differences between the two proteins (Atassi and Habeeb, 1977; Habeeb and Atassi, 
1971b). However, when the two proteins were unfolded by reduction and alkylation, 
they exhibited the expected immunochemical cross-reactions with antisera raised against 
either of the two unfolded proteins (Arnon and Maron, 1971).
Lee and Atassi (1977) showed that chemical modification (nitration) of a tyrosine 
outside an antigenic site of lysozyme creates an electrostatic inductive effect which 
disrupts the reactivity of that site. No detectable conformational changes were 
associated with this modification (Atassi, 1978).
Berzofsky et al. (1982) have concluded that 22% of myoglobin residues are 
involved in the antigenic sites, and yet 80% of evolutionary amino acid substitutions 
are immunologically detectable. Residues as far as 16& distant from an antigenic site 
have been shown to exert conformational restrictions necessary for antibody binding at 
the site (Twining et al., 1980). If all the residues within 7X of an antigenic site were 
arbitrarily considered to be important environmental residues, an additional 56% of 
Mb residues (giving a total of 78%) would be found to exert effects on its antigenicity 
(Kazim and Atassi, 1980).
Thus conformational changes in an antigen brought about by chemical 
modification or evolutionary change have been shown to be of great importance in 
influencing antigenicity. The extent and nature of conformational changes has a 
variable effect on antigenicity depending on the protein (Atassi et al., 1972; Andres 
and Atassi, 1970).
91.3 PREDICTION METHODS FOR LOCATING ANTIGENIC SITES IN 
PROTEINS
As mentioned above, proteins are composed of a number of distinct antigenic 
regions. These correspond to segments of the molecule which are accessible to an 
antibody and are specifically recognised by the antibody combining site. For example, 
antigenic sites for myoglobin, lysozyme, cytochrome C (Atassi, 1984; Benjamin et al., 
1984) and influenza virus haemagglutinin (Green et al., 1982; Muller et al., 1982; 
Wiley et al., 1981) have been reported. Although the optimal epitope size to maximise 
antibody binding efficiency is generally accepted as being between 5-10 residues (Amit 
et al., 1985), some antibodies have been shown to be capable of binding to single 
amino acids and to dipeptides (Geysen, 1985). However, the precise nature of the 
interaction between a monoclonal antibody molecule and an epitope has been defined 
by X-ray crystallography of the immune complex with the enzyme lysozyme (Amit et 
al., 1986) and with influenza virus neurominidase (Colman et al.. 1987).
Since the experimental analysis of antigenic sites is an arduous and time consuming 
procedure, much work is being performed to try and find a predictive approach for 
locating the antigenically important sites on a protein. Following correlation studies of 
known protein antigenic structures (found by experimental means) with various 
physical parameters, using computer analysis, some predictive methods have been 
suggested. These parameters include hydrophilicity, mobility, accessibility and surface 
protrusion. They are discussed in the following sections.
a) Hydrophilicity
Hydrophobic amino acids tend to be buried within the interior of globular proteins 
whereas hydrophilic ones tend to be on the exterior, where they can interact with
10
water in order for the protein to be stable in an aqueous environment (Van 
Regenmortel and de Marcillac, 1988). Kyte and Doolittle (1982) pointed that, ideally, 
the most satisfying way to determine the hydrophobic or hydrophilic inclinations of a 
given amino acid side-chain would be to measure its partition coefficient between 
water and a non-interacting, isotropic phase and to calculate from that partition 
coefficient a transfer free energy. So, they showed that, by evaluating the hydrophilic 
and hydrophobic character of stretches of residues along a polypeptide chain, it should 
be possible to distinguish regions of the sequence that are buried from those that are 
on the outside of the protein. This approach was used by Hopp and Woods (1981; 
1983) and they suggested that the most hydrophilic segments of a sequence of various 
proteins would correlate well with antigenicity, because these segments are most likely 
to be on the external surface of a protein. Each amino acid was assigned a numerical 
value (hydrophilicity value) based on the polarity of its side chain. The hydrophilicity. 
values were based on solvent parameters which represent the measured free energy of 
transfer of the amino acid from water to ethanol (Levitt, 1976; Nozaki and Tanford, 
1971). These values were repetitively averaged for overlapping sets of 6 residues along 
the peptide chain. Plotting these averages against the residue number of the leading 
residue gives a hydrophilicity profile, where a positive value indicates an above 
average hydrophilicity. Hoop and Woods (1981) in work carried out on 12 different 
proteins for which antigenic sites were known, showed that the point of highest local 
average hydrophilicity was invariably located in, or immediately adjacent, to an 
antigenic determinant.
This approach was then used to identify potential antigenic sites of hepatitis B 
surface antigen. Following chemical synthesis of the most hydrophilic peptide 
predicted, it was experimentally shown that this corresponded to a major antigenic 
determinant of that virus (Hopp and Woods, 1981; 1983). However, the secondary 
peaks of hydrophilicity do not always correlated well with known antigenic sites. For 
instance, Atassi (1984) has pointed out that only 2 of the 5 main antigenic sites of
11
myoglobin coincide with hydrophilicity maxima, and some hydrophilicity maxima are 
not antigenic. For influenza virus haemagglutinin, a strongly immunogenic region has 
been reported which is so hydrophobic that the corresponding synthetic peptide is 
insoluble in aqueous solvents (Atassi and Webster, 1983).
b) Accessibility
Atassi, 1984 showed that, for antibodies to bind a protein antigen in solution, 
antigenic sites should be accessible on the surface of the native protein. As defined, the 
accessibility of a group of atoms is proportional to its exposed surface area. So, the 
term "accessibility surface area" was introduced by Lee and Richards (1971) to 
describe the area over which contact between protein atoms and water molecules can 
occur. Molecular surface calculations can be performed on a protein of known 
structure by mathematically rolling a solvent water molecule over the van der Waal’s 
surface of the protein (Lee and Richards, 1971). Novotny et al. (1986) have shown 
that antigenic determinants in proteins coincide with surface regions accessible to large 
probes comparable in size to an antibody combining region.
However, exceptions have been found to this requirement for antigenicity. When a 
MAb isolated from a mouse immunized with native swMb was used in a competitive 
ELISA, native swMb failed to compete for antibody with swMb bound directly to an 
ELISA plate. However, the MAb did bind swMb, horse Mb and a synthetic peptide by 
direct ELISA. Clearly this MAb recognises a sequential epitope which is only readily 
accessible when myoglobins are adsorbed onto a surface (Geysen, 1985). This might 
suggest that antigen (swMb) was denatured as a result of binding to the ELISA plate 
and that the MAb was directed against the denatured form.
Studies with monoclonal antibodies directed against the / ^ “Subunit ° f  E- coli 
tryptophan synthase have shown that some antibodies bind rapidly to the native
12
antigen in solution, while others preferentially recognise the antigen only when it has 
been adsorbed onto the surface of ELISA plates (Friguet et al., 1984; Djavadi- 
Ohaniance et al., 1984).
Thus antibodies can be induced, during antigen presentation to epitopes which are 
inaccessible to antibody when the native antigen is in solution. However, this 
conclusion is based on characterization of the binding specificity of MAb. The 
relevance of these results to the overall antibody response, as represented by the 
antibody population is a polyclonal anti-serum, is unclear.
c) Protrusion index
This procedure is an extension of accessibility and takes account of the extent to 
which a residue protrudes out, from a globular protein, into the solvent. Thornton et 
al. (1986) calculated equimomental ellipsoids to fit proteins of known crystallographic 
structure, to evaluate the protrusion of a residue. A 90% ellipsoid included 90% of the 
atoms of the protein within it, with 10% lying outside or protruding from the globular 
shape. Each residue was assigned a "protrusion index" PI, specifying the ellipsoid at 
which that residue first becomes external. For instance, all residues outside the 90% 
ellipsoid were assigned a PI=9, those outside an 80% ellipsoid assigned PI=8 , etc. 
Following assignment of PI values to all the amino acids of myoglobin, lysozyme and 
myohaemerythrin, plots were drawn of PI value versus residue number. A good 
correlation was found between residue PI maxima, and the locations of amino acids 
involved in known antigenic sites of these proteins.
For future use, where only the primary sequence is available, the same researchers 
have averaged the PI values of the amino acids found from known structures to give 
predicted protrusion values for each amino acid (Thornton et al., 1985). From the 
protein primary sequence, residue PI is plotted against amino acid sequence number in
13
order to identify likely protrusive regions.
d) Mobility
Protein molecules in solution are not static structures and their functional activity 
is often linked to dynamic conformational variations (Pain, 1983; Karplus and 
McCammon, 1983). Most of the information about local mobility (conformational 
changes) in proteins has been derived from nuclear magnetic resonance (NMR) studies 
and from the X-ray crystallographic refinement of protein structures (Ringe and 
Petsko, 1985). These refinement methods provide not only precise atomic coordinates, 
but also the atomic temperature factors, which are known as B factors (Frauenfelder 
et al., 1979). The temperature factor represents the mean-square displacement of each 
atom, and when plotted versus residue number provides a graphic image of the degree 
of mobility existing along the polypeptide chain (Williams and Moore, 1985).
Information from these techniques is not readily available at present for many 
proteins, and mobility predictions are certainly not applicable to cases where only the 
primary sequence is known (Berzofsky, 1985).
To study the relationship between antigenicity and mobility two different 
approaches have been used, the binding of antibodies to peptides and the binding of 
antibodies to proteins. Anti-protein antibodies are made against the most 
conformationally restricted states of the molecule, whereas anti-peptide antibodies are 
made against a conformationally less restricted epitope (Berzofsky, 1985).
Tainer et al. (1984) raised polyclonal antibodies against 12 synthetic peptides, each 
of between 10-15 amino acid residues, covering 70% of the exposed molecular surface 
area of the myohaemerythrin molecule, as defined by X-ray crystallography. A very 
good correlation was found between mobility of segments in the native protein and the 
ability of anti-peptide antibodies to bind to these sites on the native protein in
14
solution. This correlation was shown to be with the mobility of exposed surface 
regions, and not just due to surface exposure. However, highly exposed amino acids do 
tend to be less hydrophobic and due to their external relatively unconstrained position 
are more highly mobile than internal residues (Levitt, 1983).
Thus, the mobility of a segment of the native protein is a critical factor in 
determining the ability of antibodies against short peptides corresponding to that 
segment to bind to the native protein.
A second approach to examine the mobility of antigenic sites was to use antibodies 
against the native protein. The tobacco mosaic virus protein (TMVP) was shown to 
have 7 continuous antigenic determinants as identified using tryptic peptides (Altschuh 
et al.. 1983; Milton and Van-Regenmortel, 1979). When the positions of these antigenic 
determinants were superimposed on a plot of temperature factors of main chain TMVP 
atoms, it was found that all seven antigenic regions corresponded to mobility peaks 
(Westhof et al., 1984). This correlation was better than that between antigenicity and 
either hydrophilicity or accessibility. Similarly, a good correlation was found between 
reported continuous antigenic sites of myoglobin and segmental mobility. These same 
investigators have concluded that the entire surface of the TMVP is antigenic, 
although composed primarily of discontinuous epitopes. Al Moudallal et al. (1985) 
suggested that no single criterion can be used to distinguish generally nonantigenic 
from antigenic regions.
One explanation for the apparent correlation found between antibody binding to 
continuous epitopes and mobility is an induced fit hypothesis (Marx, 1984; Tainer et 
ah, 1984). In the induced fit model, an initial weak binding is stabilized by a 
conformational change in the antigen induced by the antibody.
Geysen (1985) has suggested how a thermodynamic analysis can be used to explain 
the interaction between antibody and antigen, allowing for the possibility of 
conformational changes occurring in both the antibody and the antigen. In contrast to 
these observations, Bahraoui et al. (1987) have reported that 2 peptides of 10 amino
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acid residues in relatively rigid regions of the scorpion toxin are antigenic and capable 
of inducing the production of antibodies, which recognize the native toxin.
e) Composite surface profile
A combination of various parameters was investigated to improve the prediction of 
antigenic sites, since there is no single parameter able to predict all the antigenic sites 
on any protein. Recently a new set of amino acid hydrophilicity indices has been 
derived from the retention times of 20 model synthetic peptides in high-performance 
liquid chromatography (HPLC) (Parker et al., 1986). These researchers have chosen 
three parameters that individually provided the highest scores at predicting antigenic 
sites, to produce a composite predictive method. These parameters were HPLC 
hydrophilicity indices, predicted accessibility (Janin, 1979) and predicted flexibility B- 
values (Karplus and Schulz, 1985). The surface profile plots for the three parameters 
are combined by taking the maximum value for each residue in order to produce a 
composite surface profile. This composite profile showed good correlation with the 
known antigenic sites for several proteins, including myoglobin, lysozyme, cytochrome 
C and influenza HA1 (Parker et al., 1986). Van Regenmortel and de Marcillac (1988) 
have reported that this is the preferred method for antigenicity prediction.
f) Surface continuousness
The surface of globular protein, as defined by X-ray crystallographic coordinates, 
is very complex and convoluted. However, visual inspection of any structure shows 
that most risdues on the surface have neighbouring residues that are distant in the 
linear amino acid sequence (Barlow et al., 1986). As mentioned earlier in section 1.2,
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protein antigenic determinants can be either continuous or discontinuous. Searches made 
for protein determinants using peptide fragments which compete with protein in 
antibody complex formation, or peptides that can be used to raise antibodies which 
crossreact with the native protein, are limited to the simulation of continuous 
determinants. However, different groups of workers (Benjamin et al., 1984; Van 
Regenmortel et al., 1984) have suggested that most determinants are discontinuous. 
Recently, Barlow et al. (1986) have used a computer method to search for "continuous 
patches" on the surface of a protein. The method involves centering a sphere of radius 
(r) on each surface atom in the protein, and calculating the proportion (F) of the 
other surface atoms enclosed by the sphere which belong to residues local in the amino 
acid sequence. If a sphere encloses only local surface atoms, that indicates a continuous 
patch. However, they have shown, by consideration of protein surfaces, that if the 
recognition zone between a protein and antibody has the same dimensions, about 20& 
diameter, as those found for the lysozyme-antibody complex by Amit et al. (1986), 
none of the antibody-binding regions on a protein’s surface will be "continuous". They 
have concluded also, that the parts of a protein’s surface which are most continuous 
fall predominantly in the loops and/or protruding regions. This suggests that in order 
to predict the regions of a protein which provide the "best" antigenic peptides, methods 
such as: hydrophilicity; mobility; protrusion index, should be used since these are 
thought to identify loops and protruding regions.
g) Structurally inherent antigenic sites
Originally it was believed that the antigenic sites on a protein antigen comprise 
regions which differ in sequence from its counterpart in the immunized host (Urbanski 
and Margoliash, 1977).
Twining et al. (1980) found that the same five antigenic sites on swMb were
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recognized by rabbit and goat antisera and by chicken, cat, pig and mouse antisera. 
Also, rabbit, goat, cat, and mouse antisera recognized the same three antigenic sites on 
lysozyme (Atassi, 1978; 1984). Atassi and his group concluded that antigenicity of the 
sites was independent of any sequence differences between the injected protein antigen 
and its counterpart in the immunized host (Atassi, 1984).
The antigenicity of proteins is conferred on certain surface regions by virtue of 
the three dimensional locations of these sites. Therefore it would follow that antigenic 
sites of conformationally related proteins are likely to have similar molecular locations. 
Using this concept it has been possible to predict by extrapolation of the three 
dimensional locations of the antigenic sites of swMb, many of the sites of human Hb 
(Kazim and Atassi, 1982) and also those of soybean leghaemoglobin, a distantly related 
haem protein (Hurrell et al., 1978).
Recently, a computer search has been performed to identify a set of peptide 
sequences, containing at least six amino acids, that occur in unrelated proteins (Wilson 
et al.. 1985). Antibodies are to be raised against these peptides and tested for cross 
reactivity against them in their different conformations in the various proteins. In this 
way it will be possible to investigate further the roles of conformation and mobility in 
antibody binding.
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1.4 STRUCTURAL DETERMINATION OF ANTIGEN -ANTIBODY COMPLEXES
The identification of antigenic regions on protein molecules has been attempted by
a variety of methods, as mentioned above (section 1.3), but the structural basis of
antigenicity remains unclear (Colman et al., 1987). However, Van Regenmortel (1987)
pointed out that it should always be remembered that antigenicity is not a structural
property per se but is a functional categorization that can be defined only by using
antibody combining sites as a detecting device. Recently, an antigen binding fragment
(Fab) of an antibody, together with its antigen, (Ag/Ab complex) has been crystallized.
The three-dimensional structure of the complex between an antigen (lysozyme) and the
Fab fragment from a monoclonal antibody against lysozyme has been determined and
refined by X-ray crystallographic techniques (Amit et al., 1986). The structure of a
complex between an antibody Fab fragment and influenza virus neuraminidase was
analysed by the same techniques, as reported by Colman et al. (1987).
Amit et al. (1986) have explained that the interface involves 16 amino acid
residues from the antigen and 17 residues from the antibody and extends over a large
o
area, with maximum dimensions of about 30 x 20 A. They concluded that the 
lysozyme antigenic determinants recognized by the monoclonal antibody are made up 
of two stretches of polypeptide chain, comprising residues 18-27 and 116-129, distant 
in the amino acid sequence but adjacent on the protein surface. This conclusion 
supports the observations made by Barlow et al. (1986), who argued that if the area
on the surface of a protein that is recognized by antibody molecules is of the order of
o . .20 x 25 A, all protein epitopes are likely to be discontinuous. This argument rests on
the premise that in all protein epitopes, the interaction occurs over a surface of about 
o
20A diameter. On the other hand, Van Regenmortel (1987) has reported that some 
residues in a continuous epitope can be replaced by any of the 19 amino acids without 
impairing the antigenic activity, whereas others cannot be substituted at all. This 
means that not every residue in the so-called continuous epitope is in contact with the
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antibody and that the linear peptide is in fact antigenically discontinuous. It has been 
suggested by Westhof et al. (1984) that the antigenic regions of proteins are located in 
the more flexible chain segments, which may adopt a configuration that allows 
antibody binding. But, Amit et al. (1986) concluded in the case of their monoclonal 
Fab-lysozyme complex, that the parts of the lysozyme that make contact with antibody 
are not the more flexible regions of free lysozyme, and no deformation of the antigen 
nor any structural change in the Fab was observed. They found that antibody and 
antigen fit as "lock and key" with no detectable perturbation of the lysozyme structure.
Colman and his group (1987) found, in the case of an influenza virus
neuraminidase-MAb complex, a structure which may be described as a square box 
o
(100 x 100 x 60 A) with four antennae (Fab molecules) attached to one surface on the 
outer corners. The size of the contact region formed with the Fab fragments of 
antibodies is about 700A^ (unpublished data), and there are no more contacting 
residues than the 16 or 17 which were observed in the Fab-lysozyme complex by Amit 
et al. (1986). However, they concluded that the structure of the complex between a 
monoclonal antibody and neuraminidase showed features inconsistent with a rigid "lock 
and key" model for antibody-antigen interactions. They observed, in contrast to the 
findings from a lysozyme-antibody complex by (Amit et al., 1986), an unusual Vl -Vjj 
pairing in the V module of the Fab, and local perturbation of the antigen at the 
centre of the epitope. Thus, the same group proposed that, during antigen binding, the 
Vl  and Vjj domains of the antibody slide at their interface, and that the nature of 
the Vl -Vj i  association may produce static or dynamic properties important for antigen 
binding. This suggests that there is a conformational change in the antigen and 
antibody as a result of binding. Therefore the interaction has some of the character of 
a "hand shake".
The two structural analyses to date of Fab-antigen complexes have provided rather 
different views of the way in which an antibody can bind to the surface of a protein. 
Sutton (1988) concluded, that these differences reflect the contrasting natures of the
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two epitopes, and show that while mobility may sometimes be important in 
determining antigenicity, it is clearly not a necessary feature.
SUMMARY
Experimentally, to identify protein antigenic determinants, the methods available
are:
1) Fragmentation of the native protein either by chemical cleavage or controlled 
proteolysis, followed by screening of the fragments for immunologically active 
components that bind to antibodies and can interfere with their interaction with the 
intact antigen.
2) Synthesis of peptides corresponding to potential epitopes, and measuring their 
reactivity with antibodies raised against the native protein.
and 3) Study of the antigen-monoclonal antibody (MAb) complex by X-ray 
crystallography.
By correlating the results obtained from experimental work with the predictive 
data (as discussed above) it should be possible to define the positions of the major 
antigenic sites on proteins. Most correlation studies reported in the literature have 
concentrated on small, monomeric proteins such as myoglobin, lysozyme, 
myohaemrythrin and tobacco mosaic virus protein. It is recognized that these are not 
necessarily representative of large, oligomeric proteins and that additional data are 
required before predictive methods can be reliably applied to more complex structures.
So, in this study I used the enzyme citrate synthase as an example of an oligomeric 
protein antigen because of the large amount of available structural and functional 
information on this enzyme.
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2.1 THE CITRIC ACID CYCLE
The citric acid cycle operates in most living organisms representing a broad 
spectrum of diverse life styles. Such diversity may well be reflected in the roles that 
the citric acid cycle plays in order to suit the metabolic needs of a particular 
organism, be it provision of energy or of biochemical intermediates. These roles, in 
turn, could possibly be reflected in finer detail in terms of the structural, catalytic and 
regulatory properties of the enzymic machinery of the cycle. The citric acid cycle as 
shown in Fig. 2.1 was first proposed by Krebs and Johnson (1937) to describe the 
final stages of carbohydrate oxidation by animal tissues. It is now known that this 
metabolic cycle is at the core of cellular metabolism and serves as the final oxidation 
process of all major food-stuffs in all respiring organisms (Krebs and Lowenstein, 
1960).
2.2 DISCOVERY OF CITRATE SYNTHASE
The "condensing enzyme" which brought about the combination of "active" acetate 
with oxaloacetate to form citrate, was first described by Stern et al. (1950). Later, 
"active" acetate was shown to be acetyl-CoA (Lynen and Reichert, 1951; Lynen et al., 
1951) and it was thus established that "condensing enzyme", now known as citrate 
synthase (citrate oxaloacetate-Lyase (CoA acetylating); EC 4.1.3.7) catalyses the 
following reaction:
Acetyl-S-CoA+oxaloacetate+H2 0 ----- >  citrate* CoA-SH
COOH
CH3 CO-S-Co A* HOOC-CO-CH2 -COOH+H2O —^HOO C-CH 2 -C-CH2 -COOH+ CoA -5H
OH
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Citrate synthase has been extensively studied as it catalyses the first reaction of the 
citric acid cycle and has been shown to play an important regulatory role in a cell's 
metabolism (Danson, 1988; Beeckmans and Kanarek, 1984; Weitzman, 1981; Weitzman 
and Danson, 1976; Randle et al., 1970).
In eukaryotes the citric acid cycle enzymes are exclusively mitochondrial, with the 
exception of germinating plant seeds where citrate synthase, together with enzymes of 
the glyoxylate shunt, are also found in glyoxysomes (Tolbert, 1981). Citrate synthase is 
loosely attached to the inner mitochondrial membrane of eukaryotes (Dsouza and Srere, 
1983) and is thought to be associated with the cell membrane of bacteria (Mitchell, 
1963). Citrate synthase apparently has a close association with other enzymes such as 
pyruvate dehydrogenase (Sumegi et al., 1980), malate dehydrogenase and fumarase 
(Beckmans and Kanarek, 1981) and aspartate amino-transferase (Fahien and Kmiotek, 
1983). Barnes and Weitzman (1986) have shown by gentle disruption of cells followed 
by gel filtration and sucrose density gradient centrifugation, that five sequential 
enzymes of the citric acid cycle (malate dehydrogenase, citrate synthase, aconitase, 
isocitrate dehydrogenase and fumarase) are specifically associated into a cluster.
2.3 DIVERSITY OF CITRATE SYNTHASES
Comparative studies of the citrate synthases of eukaryotes and eubacteria have 
shown that these enzymes possess a marked diversity of subunit structure, catalytic 
activity and allosteric regulation that shows a strong correlation with the taxonamic 
status of the source organism (Danson, 1988; Weitzman, 1981; Weitzman and Danson, 
1976). A summary of these relationships is shown in Table 2.1.
Studies on citrate synthases of eukaryotic, and Gram positive bacteria showed that 
these enzymes are inhibited by ATP (Jangaard et al., 1968; Hathaway and Atkinson, 
1965). However, Harford and Weitzman (1975) have reported that this inhibition is
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Gram positive Halio- Thermo- M ethan- 
philes acido- ogens 
philes
Mol. Wt. 270,000 270,000 90,000 110,000 85,000 90,000
Type large large small







NADH allosteric allosteric none
(reactivated (AMP has no 
by AMP) effect)




allosteric none none none yes none
ATP none none isosteric weak yes yes isosteric
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isosteric, ATP competing with the substrate acetyl-CoA at the active site.
By contrast, the citrate synthases of Gram negative bacteria, are insensitive to ATP 
(Weitzman, 1966), but they are inhibited allosterically by NADH. Within this group, 
the enzymes of obligate aerobes can be reactivated by AMP, while those of facultative 
anaerobes cannot (Weitzman, 1981). Citrate synthases of Gram positive bacteria and 
eukaryotes, however, are generally much less inhibited by NADH, than those of Gram 
negative bacteria (Weitzman and Danson, 1976).
Inhibition of citrate synthase by 2 -oxoglutarate was shown to be allosteric and only 
occurred in facultatively anaerobic Gram negative bacteria (Weitzman and Dunmore, 
1969).
An investigation of the molecular sizes of the citrate synthases of Gram negative 
bacteria has shown these enzymes are hexameric molecules with molecular weight of 
approximately 270,000 (Robinson et al., 1983a; Tong and Duckworth, 1975). The 
citrate synthases of Gram positive bacteria and eukaryotic organisms have molecular 
weight values of approximately 90,000 and are dimers (Robinson et al., 1983b; 
Weitzman, 1981). However, it should be noted that the subunit sizes in both types of 
the enzyme, "large" and "small", are identical and are in the range 43,000-49,000.
As pointed out above, Gram positive bacterial citrate synthases are "small". There 
also exists another group of bacteria known as the Archaebacteria comprising the 
thermoacidophiles, halophiles and methanogens. These are not Gram positive, but they 
possess "small" citrate synthases. They represent a category of organisms which 
constitute a third evolutionary line of descent (Woese, 1981). In studies on 
thermoacidophile citrate synthases, they have been shown to be dimers of total 
molecular weight 85,000. They are sensitive to inhibition by ATP (Danson et al., 
1985). Halophiles also have the small type of citrate synthase and are inhibited only 
weakly by ATP. Citrate synthase from the methanogen Methanosarcina barkeri was 
unusually inhibited by ATP, NADH and 2-oxoglutarate; however the enzyme is 
present in very low amounts and therefore its molecular size has not yet been
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determined (Danson et al.. 1985).
In summary, only the "large" citrate synthases have shown allosteric regulation, 
while the regulation of the "small" enzyme is isosteric.
A complementary approach has been used by Danson et al. (1979) to study the 
structure/function relationships of citrate synthases. This was achieved using the 
facultative anaerobe Escherichia coli. The "wild type" of this organism produces a 
heaxameric citrate synthase, which is sensitive to allosteric inhibition by both NADH 
and 2-oxoglutarate (Weitzman and Danson, 1976). From mutagenesis work, a mutant 
of E. coli was produced, in which the citrate synthase was now dimeric and was 
insensitive to inhibition by either NADH or 2-oxoglutarate (Danson et al., 1979). The 
apparently minor genetic alterations involved in this conversion emphasize the strong 
relationship between the structure and function of citrate synthase, and may mimic 
natural mutations which have occurred to produce the existing diversity of citrate 
synthases.
2.4 THE PRIMARY SEQUENCES OF CITRATE SYNTHASE FROM PIG 
HEART, YEAST, E. COLI R. PROWAZEKII AND A. ANITRATUM
Amino acid sequencing of fragments of pig heart citrate synthase (PHCS) produced 
by proteolytic (Bloxham et al., 1980) and chemical means, has provided the complete 
amino acid sequence of this enzyme (Bloxham et al., 1982; Bloxham et al., 1981), see 
Fig. 2.2.
For citrate synthase of E. coli, the primary sequence data were first obtained from 
sequencing the gene (Ner et al., 1983). Amino acid sequencing performed on fragments 
produced by proteolytic and chemical digests of E. coli citrate synthase has since 
confirmed the majority of this sequence (Bhayana and Duckworth, 1984).
Suissa et al. (1984) have determined the nucleotide sequence of citrate synthase of
Fig. 2.2 Comparison between the amino acid sequences of citrate synthase from pig, heart, yeast 1, 2 , 
E. coli, R. Prowazekii and A. anitratum.
The sequences are aligned to maximise homologies.
Numbering relates to the sequence alignment and does not correspond to any single sequence. 
This alignment supplied by Dr. C. Henneke.
1 10 20 30 40 50 60 70 80 90 100 110 120 130
ASS-TN-LKDILADLIPKEQARIKTFRQQH-GNTVVGQlf-VDMMYGG--M-RGMKGLVy-ETSVL5pD--EGIRF-RGYSIPECQKMLPKAKGGEEPLPEGLFWLLVfGQIPTEEQVSWLSKEWAKRAA 
ASEQT--LKERFAEII PAKAQEI KKFKKEH-GKTVIGEVL-LEEQAYGG-M-RGI KGLVW-EGSVLDPE--EGIRF-RGRTIPEIQRELPKAEGSTEPLPEALFWLLLTGEI PTDAQVKALSADLAARSE 
SQEKT--LKERFSEIYPIHAQDVRQFVKEH-GKTKISDVL-LEQVYGG - -M-RGI PGSVW-EGSVLDPE-D-GI RF-RGRTI ADI QKDLPKAKGSSQPLPEALFWLLLTGEVPTQAQVENLSADLMSRSE
AD--T KAKLTLNGDTAVELDVLKGTL--GQDVI -DIRTLGSKGVF-TFDPGFTSTASCESKITFIDGDEGILLHRGFPIDQLATDSN-Y-------L-EVCYILLNGEK-PTQEQYDEFKTTVTRHTM
TNGNNNNLE--FAELKIRGKLFKLPILKASIGKDVI -DI SRVSAEADYFTYDPGFMSTASCQSTITYIDGDKGILWYRGYDIKDLAEKSD-F-------L-EVAYLMIYGEL-PSSDQYCNFTK K VAHHSL
-SEATGK-KAVLHLDGKEIELPIYSGTLGP DVI -DVKDVLASGHF-TFDPGFMATASCESKITFIDGDKGILLHRGYPIDQLATQAD-Y-------L-ETCYLLLNGEL-PTAEQKVEFDAKVRAHTM
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LPSHVVTMLDNFPTNLHPMSQLSAAITALNSESNFARAYAEGIHRTK YWELI YEDCMDLIAKLPCVAAKIYRNLYREGSSIGAIDSKLDWSHNFTNMLGYTDAQ--FTELMRLYLTIHS------- DHEGG
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VNERLHYLFQTFCSSSHPMAIMLAAVGSLSAFYPDLLNFNETDY-ELTAIRMIAKI PTIAAMSYKYSIGQPFIYP-D--------NS-LDFTENFLHMMFATPCTK-YKVNPIIKNALNK I FI LHADHEQ-
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VERKLYPNVDFYSGIILKAIGIPTE-MFTVIFALARTVGWISHWLEMHSGPYK-IGRPRQLYTGEVQRDIK------R
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yeast. The amino acid sequence, derived from the nucleotide sequence, shows that this 
citrate synthase has a strongly basic amino-terminal region (Fig. 2.2). It has been 
proposed that this amino-terminal region is removed during translocation of the 
precursor into the mitochondria.
Recently, DNA-derived sequences of Rickettsia Prowazekii (Wood et al., 1987) and 
Acinetobacter Anitratum (Donald and Duckworth, 1987) citrate cynthases have been 
reported, see Fig. 22.
It can be seen from Fig. 2.2, that a substantial degree of sequence resemblance 
exists between the citrate synthases of pig heart and yeast (Garforth, 1985). However, 
E. Coli citrate synthase shows limited regions of homology with both the citrate 
synthases from pig heart and yeast, but this is less than the homology between the two 
eukaryotic enzymes. Residues shown to be necessary for catalysis in PHCS are highly 
conserved in both the yeast and E. coli enzymes. These include His 235, His 238, His 
320, Arg 329 and Asp 375 (Suissa et al., 1984).
Recently the sequence of the gene for CS from pig tissue has been determined 
(Evans et al., 1988). This sequence confirms the previous data obtained by amino acid 
sequencing.
2.5 CITRATE SYNTHASE STRUCTURE
Studies on the crystallograhic structure of citrate synthase from pig heart 
(Remington et al., 1982; Wiegand et al., 1979) showed that the individual polypeptide 
chains were folded predominantly as helices. Thus the enzyme has been shown to 
contain 40 helices per dimer, packing tightly to form a globular molecule. Fig 2.3 
represents the schematic structure of one monomeric unit of the dimeric enzyme. It has 
been shown that this monomer is divided structurally into two domains. The larger 
domain contains residues 1-274 (helices A to M) and residues 381-437 (helices S and
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Fig .  2 . 3  Conformation o f  PHCS monomer as determined b.y X-ray  
c r y s t a l lo g r a p h y
h e l i c a l  segments
A 5 -  29 K 221 -  2 3 6
B 37 -  43 L 2 4 2 -  2 5 5
C 7 0 -  78 M 2 5 7 -  271
D 8 8 -  99 N 2 7 4 -  291
E 1 0 3 -  1 1 8 0 2 9 7 -  3 1 2
F 121 -  131 P 3 2 7 -  341
G 1 36 -  1 5 2 Q 3 4 4 -  3 6 5
H 1 5 3 -  161 R 3 7 3 -  3 8 6
I 1 6 3 -  1 9 5 S 3 9 0 -  4 1 6
J 2 0 8 -  2 1 8 T 4 2 6 -  4 3 3
The t a b l e  shows the amino ac id  r e s id u e s  a t  the beg inning  and end 
o f  each h e l i c a l  segment. (Remington e t  a l . , 1982) .
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T), while the smaller domain has residues 275-380 (helices N to R). The subunits are 
extensively interdigitated, with amino acid residues from one subunit contributing to 
the binding of citrate and CoA to the other subunit.
The structure of the enzyme has been described in three states (Wiegand et al., 
1984; Remington et al., 1982). It has been proposed that binding of oxaloacetate to the 
‘’open" form of the enzymes induces a "closed" form in which the binding site for CoA 
is developed. A further "closed" form is found which has bound citrate. Lesk and 
Chothia (1984) and Chothia and Lesk (1985) have studies the conformational changes 
in response to changes in the state of ligation. The conformational forms of the 
enzyme were explained in terms of helix movements, the most pronounced being the 
movement of helix O on the outside of the small domain. This is in agreement with 
the proposal of Wiegand et al. (1984), who suggested that the small domain is more 
flexible than that the large one.
2.6 IMMUNOCHEMICAL STUDY OF CITRATE SYNTHASE
An antiserum raised against rat heart citrate synthase was able to cross-react with 
rat liver, kidney, brain and spleen enzymes, using Ouchterlony double diffusion 
technique (Moriyama and Srere, 1971). No reaction, however, was seen with PHCS, or 
CS from moth muscle, Azotobacter, or mango. Matsuoka and Srere (1973) used this 
antiserum for enzyme precipitation and in double immunodiffusion experiments, 
suggested that the rat kidney CS, heart CS and brain CS are immunologically identical.
Other antisera raised against yeast CS have proved useful for the precipitation of 
the translation products of mRNAs, to identify which mRNAs could be used to 
produce cDNA sequences coding for CS (Suissa et al., 1984; Alam et al., 1982).
Further experiments using double diffusion and immunoprecipitation were carried 
out on different proteolytic digestion mixtures of PHCS in an attempt to discover
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which domain of PHCS had the greater antigenicity (Bloxham, et al., 1980). The 
relative impurities of the fragments used in this assay, however, may overrule the 
conclusion that the small domain is the primary antigenic domain.
Pullen et al. (1985) have reported an immunochemical investigation of interspecies 
diversity, using rabbit antibodies raised against PHCS. In a competition enzyme-linked 
immunosorbent assays, where plates were coated with pigeon breast CS, they showed 
the order of competition to be PHCS > pigeon breast CS > Bacillus megaterium CS > 
E. coli CS. The same order of reactivity was shown in enzyme inhibition experiments. 
Cross-reactivity was also studied by examining the ability of the rabbit anti-PHCS 
immunoglobulins to precipitate out enzyme activity from solution using Staphylococcus 
aureus protein A as a cross-linking agent. In this assay both the PHCS and E. coli CS 
tested were shown to be precipitated. This work shows conclusively that, in addition to 
species-specific determinants, the citrate synthases from pig heart, pigeon breast, B. 
megaterium and E. coli share common antigenic epitopes.
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AIMS OF THIS STUDY
The aim of this work is to study the antigenicity of the enzyme pig heart citrate 
synthase (PHCS) by comparing experimentally identified epitopes, with epitopes 
identified using predictive methods. So, the work will include:
1. Prediction of potential epitopes.
2. Synthesis of selected peptides corresponding to potentially antigenic regions of 
PHCS.
3. Examination of their antigenicity with antibodies raised against native PHCS.
4. Use of these synthetic peptides as immunogens to raise serum antibodies.
5. Examination of the reactivity of anti-peptide sera against each peptide and 
native PHCS.
6 . Determination of the ability of these anti-peptide sera to block the binding of 
MAb to native PHCS.
7. Comparison of rabbit-anti PHCS with these anti-peptide sera on immunoblots, 
against native PHCS and fragments of PHCS.
8 . Study of the effect of anti-peptide sera on enzyme activity.
Fig. 2.4 schematically represents these aims.
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Fig. 2.4 Locating major antigenic sites in PHCS using a combination of both 
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All chemicals used were of analytical grade, unless stated in text, and were 
purchased from either Sigma (UK) Ltd or BDH Ltd. Pig heart citrate synthase 
(PHCS) as a suspension in 22M  (NH4 )2S0 4  solution pH 7.0, was obtained from 
Sigma. Polyclonal and monoclonal antibodies (MAb’s) against PHCS were obtained 
from previous work in our laboratory.
All conjugated antibodies were obtained from Sigma; anti-rabbit IgG alkaline 
phosphatase and anti-mouse IgG alkaline phosphatase, were as suspension in 0.05M tris 
pH 8.0, and anti-rabbit IgG peroxidase was as a suspension in 0.01M phosphate 
buffered saline pH 7.4. Table 3-1 shows the amino acid derivatives and resin used for 
peptides synthesis which were purchased from Milligen (manufactured by Cambridge 
Research Biochemical (CRB), Ltd). N,N-dimethylformamide (DMF) (vacuum distilled 
prior to use), trifluoro acetic acid (TFA) (distilled from KMn0 4 ) and piperidine were 
from Aldrich Chemical Co. Ltd.
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Table 3.1 The amio acid derivatives used in the peptides synthesis
amio acid derivative used in peptide synthesis
Ala Fmoc -  Ala - OPfp
Arg Fmoc - Arg (Mtr) - OH
Cys FmoC - Cys (Trt) - OPfp
Asp Fmoc -  Asp (OBu*) - OPfp
Gin Fmoc -  Gin - OPfp
Glu Fmoc - Glu (OBu*) - OPfp
Gly Fmoc - Gly - OPfp
Leu Fmoc -  Leu - OPfp
Lys Fmoc - Lys (Boc) - OPfp
Met Fmoc - Met - OPfp
pro Fmoc - Pro - OPfp
Ser Fmoc - Ser (Bul) - ODhbt
Val Fmoc - Val - OPfp










All solutions were prepared using glass-distilled or double-distilled water. Buffers, 
such as 0.05M carbonate pH 9.8 and 0.15M phosphate buffered saline (PBS) pH 7.2, 
were made as described by Hudson and Hay (1974) or Johnstone and Thorpe (1987).
METHODS
3.3 SYNTHESIS OF PEPTIDES
The solid-phase method of peptide synthesis was first introduced by Merrifield 
(1963). Recently an alternative chemistry (Fmoc polyamide active ester) has been 
developed and improved over the past few years by Sheppard and co-workers at 
Cambridge Research Biochemical (CRB).
a) Basis of the method
In solid-phase synthesis, peptide chains are assembled from the carboxy terminus, 
one amino acid at a time, towards the amino terminus.
The first (carboxy terminal) amino acid is attached by forming a chemical bond to 
an insoluble supporting resin via an acid chemical linking agent. In subsequent steps, 
Carboxy group activation is by an active ester, pentafluorophenyl (Pfp). The remaining 
amino acids are added one by one until the peptide assembly is complete. The amino 
(NH2 -) group of each amino acid is protected by substitution with a 9- 
fluorenylmethoxycarbonyl (Fmoc) group. This group is removed once coupling of the 
amino acid to the growing peptide is complete. The chemistry of initiation and one 
further cycle of solid-phase peptide synthesis is illustrated in Fig. 3.1.
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Fig. 3.1 Schematic diagram of peptide synthesis
(Fmoc-Arg) 2 0  + HO-Resin
Attachment 4 -dimethy laminopy ridine
Fmoc-Arg-O-Resin










One cycle for synthesis of peptide PCS-1 as started with residue no. 302 arg followed 
by leu ... etc.
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b) Coupling reaction and the test for complete coupling
The first (C-terminal) Fmoc amino acid residue was bound to the resin through 
the formation of an ester bond using 4 -dimethylaminopyridine (DMAP) in DMF. 
Deprotection of the N-terminal amino group was achieved using 20% piperidine in 
DMF and then coupling of the following amino acid was achieved using the 
pentafluorophenyl (Pfp) ester (activation) of the Fmoc amino acid. Elongation of the 
peptide chain was performed stepwise until the N-terminal amino acid was reached.
1.1 g of resin was used with a capacity of 0.1 meq/g and amio acid derivatives were 
used as 4 fold excess.
Pfp esters were dissolved in the minimum volume (1 -2ml) of DMF (with 1 - 
hydroxybenzotriazole (HOBT) acting as a catalyst) before being loaded to the peptide 
synthesiser. The reaction was left for coupling for 25 min. and again deprotection 
using 20% piperidine in DMF was effected as shown in Fig. (3-1).
To check completion of the coupling reaction prior to deprotection, the "Kaiser 
test" was used. This test uses three reagents which are: 5% ninhydrin in ethanol, 400% 
phenol in ethanol and 2% 0.001M KCN in Pyridine; a blue colour is formed in the 
presence of free amino groups. A few grains of resin were taken from the top of the 
column just after the end of coupling time of each activated Fmoc amio acid loaded; 
this resin was washed on a small sintered glass filter with 10 ml each of DMF, DCM 
and ether then dried on an air line. The dried grains were then transferred to a tube 
(0.5x5 cm) and one drop each of the three Kaiser test reagents were added. The 
mixture was heated for 5 min at 100°C. Complete coupling is confirmed by a pale 
yellow colour. If the coupling is incomplete (as seen by the development of a blue 
colour), either the reaction time can be extended or fresh acylating agent can be added.
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c) Cleavage of the assembled peptide
After complete assembly of the required peptide, final deprotection was carried out 
using 20% piperidine in DMF. The column was removed from the peptide synthesiser 
and the contents of the column (peptide-resin) were washed with 40ml each of t-amyl 
alcohol, acetic acid, t-amyl alcohol, and ether, after which the resin was dried using 
an air line. The required amount of peptide from the total amount of peptide-resin was 
weighed out and suspended in TFA (8.5 mg/ml) which contained a specific scavenger. 
It is necessary to add scavengers (5-10%) to the TFA to prevent side reactions with 
the released peptide. Commonly used scavengers are: water, phenol, ethylmythyl- 
sulphide, and ethanedithiol. The choice of scavenger depends upon the amio acid 
composition of the peptide. So in the presence of arg as in peptide PCS-1, the 
scavenger was 5% (w/v) phenol and in the presence of met in peptide PCS-2, 5% 
(v/v) ethylmethylsulphide was used as a scavenger. After cleavage for 18h in the case 
of PCS-1 and for 2-3h in the case of PCS-2, the resin was removed by filtration 
through a sintered funnel and the filtrate evaporated under reduced pressure to remove 
TFA. The peptide residue was then dissolved in 1-2 ml of double-distilled water and 
freeze-dried overnight. The dry peptide was collected, weighed and stored at -20°C.
3.4 AMINO ACID ANALYSIS
Amino acid analysis was used to confirm the composition of the synthetic peptides. 
Duplicate aliquots of 10 and 20/d (containing approximately 10 and 20/tg peptide) of 
each synthetic peptide were hydrolysed at 110°C for 24 and 48h in 200/d of 6M HC1, 
in evacuated sealed tubes. Then, the hydrolysates were dried in a vacuum desiccator 
and resuspended in 25mM HC1 (200/d) and subsequently loaded onto the amino acid 
analyser (Rank-Hilger chromaspek II).
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3.5 PURIFICATION OF SYNTHETIC PEPTIDES
The crude peptides were desalted by gel filtration on a Bio-Gel P2 column 
(1x15 cm), eluting with 0.05M acetic acid. Peptide elution was monitored by 
absorbance at 230 nm. Then fractions containing the first absorbance peak were pooled 
and freeze-dried.
Peptides were further purified by fast protein liquid chromatography (FPLC) using 
a Pharmica FPLC system. Samples of peptide (dissolved in lOmM sodium acetate) were 
loaded onto a Mono S anion exchange column and the bound peptide was eluted with 
an NaCl gradient of 0.5M. (This Mono S column was used as a cation exchanger with 
-CH2 -SO3 groups, so that the positively charged protein will bind). The separation was 
monitored by absorbance at 215 nm. The fractions containing the peptide peak were 
pooled and freeze-dried. Aliquots were taken for amino acid analysis. After 
purification, samples of synthetic peptides (1 mg/ml dissolved in acetonitrile) were 
tested for purity by HPLC on a Gilson reversed-phase C-18 column (0.46x25 cm) 
using an acetonitrile gradient (of 5% - 95% (v/v)). The purified material gave a 
single symmetrical peak as monitored by a uv detector at 214 nm.
3.6 PREPARATION OF ANTI-PEPTIDE ANTIBODIES
a) Extension of synthetic peptides and coupling to carrier protein
Two synthetic peptides, each of 15 amino acid residues (PCS-1 and PCS-2 
corresponding to residues 288-302 and 76-90 of the PHCS sequence respectively), were 
synthesised as described in section 3.3, and before cleavage the peptides from the 
resins, both peptides were extended with two more amino acid residues using the same 
Fmoc technique. The additional amio acids were glycine, which was used as a spacer,
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and cysteine. The cysteine residue was added to the amino terminus of the peptides to 
allow coupling to a protein carrier. Then, the extended synthetic peptides were cleaved
from the resins as described in section 3.3.
The extended peptides were coupled to the carrier protein keyhole limpet 
hemocyanin (KLH). The carrier protein was activated with N-maleimidobenzoyl-N- 
hydroxysuccinimide ester (MBS) and subsequently coupled to the peptide through its 
cysteine residue (Liu et al., 1979; Green et al.. 1982) as shown in Fig. 3-2.
For each peptide, 4 mg KLH in 250 /il of lOmM sodium phosphate buffer, pH 
7.2, was reacted with 0.7 mg MBS (dissolved in 50-70 /il DMF), added dropwise with 
stirring for 30 min at room temperature. The reaction product, KLH-MB, was then
passed through a Sephadex G-25 column (1x15 cm), equilibrated with 50mM sodium
phosphate buffer, pH 6.0, to remove free MBS. KLH-MB was recovered by pooling 
fractions for the first peak of the column eluate (monitored by A28 0 ) and then 
reacted with peptide (5mg dissolved in 1ml of PBS). The pH was adjusted to 7-7.5 
and the reaction was stirred for 3h at room temperature. The mixture was stored at 
-20°C until required for immunisation.
b) Immunisation method
Six rabbits were used, two for each peptide-carrier conjugate and two for the 
carrier protein (KLH). Rabbits were injected intramuscularly with 1ml of immunogen 
(200/ig of protein); injections were given in the hind limbs at multiple sites, according 
to the following schedule:
day (0) 1st injection: equal volumes of each immunogen and Complete Freund’s 
Adjuvant were mixed and homogenised several times until an emulsion was obtained, 
day (14) 2nd injection: as above but using Incomplete Freund’s Adjuvant, 
day (28) 3rd injection: aluminum potassium sulphate (alum) - precipitated 
immunogen. Each immuogen (0.5ml) was mixed with 0.2M alum (0.5ml) and 1M
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Fig. 3.2 Peptide-Carrier conjugation using the MBS method
s- ch 2- c h - n h ^
i
C O 2 H  ,
P E P T I D E
P R O T E I N  - NH
PEPTIDEC Y SM B SPROTEIN
C arrier protein : Keyhole Limpet Hemocyanin
MBS : N -maleimidobenzoyl-N -hydoxysuccinimide ester
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NaHCOj (0.22ml) was added, and the mixture was left for 15min at room 
temperature. Then the precipitate was collected by centrifugation at 300g (1500 rpm) 
for 15 min and the insoluble protein resuspended in PBS prior to immunisation.
After the initial course of injections, the rabbits were boosted with the same 
amount of alum-precipitated immunogen given at intervals of 1 and 2 weeks.
c) Preparation of Sera
Immunised rabbits, one and two weeks after an antigen boost (as mentioned 
above), were ear-bled for 10-15ml of blood each time. Five bleeds were taken and the 
fifth bleed was used in all the assays for this study.
Blood was left for 4-5h at room temperature, then overnight at 4°C for clotting. 
Clots were then removed by centrifugation, in a bench MSE centrifuge, at 2000g 
(4,000 rpm) for 15min and the serum was given a second centrifugation at llOOOg 
(10,000 rpm) for 15min. Serum was collected and stored at -20°C in aliquots.
d) Immunoglobulin preparation from sera
An equal volume of saturated ammonium sulphate solution was added to rabbit 
serum. Following a 30min incubation at 4°C, with periodic stirring, the precipitate 
was collected by centrifugation at 5,000 g for 20 min. The pellet was redissolved in 
1ml of PBS and dialysed against 20mM tris buffer, pH 8.0, at 4°C.
e) Protein determination
The concentration of protein was estimated spectrophotometrically (Layne, 1957). 
The absorbance of a suitably diluted protein solution was measured at both 260nm and 
280nm against a buffer blank. The following formula was applied to calculate the
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protein concentration in mg/ml;
protein concentration ■ (1.55 x A280  -0-77 x A jgo)
3.7 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
ELISA reactions were carried out using flat-bottomed rigid polystyrene EIA strips 
(Titertek, Flow Lab.).
a. Direct ELISA
In this technique, the antigen is immobilised by direct attachment to a solid 
support (plastic sides of microtitre wells). Wells were coated with a solution of PHCS 
(10 /xg protein/ml) in 0.05M sodium carbonate buffer, pH 9.8 (150 /xl) for 18h at 
4°C. Then the contents of the wells were tipped out and the plate blocked by 
incubation for 30min at 37°C with 150 /xl of 1% (w /v) casein in PBS, followed by
washing 4x5min with PBS containing 0.05% (v/v) Tween 20. Antibodies (150 /xl), at
different dilutions in PBS, were added and incubated for 2h at 37°C, followed by
washing for 4x5min. The plates were then incubated for 2h at 37°C with 150 /xl
enzyme-antibody conjugate (as mentioned in section 3-1), diluted 1:1000 in 1% (w/v) 
casein/PBS. After washing for 4x5min, an enzyme substrate (150 /xl) was added and 
the colour produced was read by using a "Titertek Uniskan" microtitre plate reader 
with a 405 nm filter.
b) Sandwich ELISA
Wells were coated with 150 /xl rabbit IgG anti-citrate synthase (10 /xg protein/ml 
in carbonate buffer) for 18h at 4°C, and were then blocked with 1% (w /v) casein in
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PBS and washed. Antibody-coated wells were incubated with citrate synthase (10 
/xg/ml in PBS) for 2h at 37°C. Following this, the subsequent steps of the assay were 
carried out as described above.
c) Competitive ELISA
In this ELISA technique, all the steps explained above were used, except that the 
antibody was incubated with varying amount of antigen (as competitor) prior to 
transfer to the wells. That is, 200/xl samples of antibody (20 /xg/ml) were incubated 
with 200/il of antigen at various concentrations (0, 4, 10, 40, 100 /xg protein /m l) for 
lh  at 37°C. Then duplicate 150/tl samples of this mixture were added to the wells of a 
plate, previously coated with antigen. Then the subsequent steps of the assay were 
carried out as described above.
3.8 CHEMICAL FRAGMENTATION OF PHCS
a) Cleavage of asp-pro peptide bonds with mild acid was achieved according to 
Rittenhouse and Marcus (1984). PHCS (0.12 mg/ml) was incubated at 110°C with 
15mM HC1 in sealed tube. Termination of the reaction was accomplished by rapid 
cooling and freezing to - 70°C, and the digests were then freeze-dried overnight. The 
samples were reconstituted in water for running in SDS-PAGE (section 3.11).
b) CNBr cleavage at met was performed according to Gross (1967). PHCS 
(5mg/ml) was dialysed against 70% (v/v) formic acid at 4°C and solid CNBr 
(2mg/ml) was added to this solution. The reaction was carried out for 18-20h at room 
temperature in the dark, followed by dilution of the reaction mixture with 5-10 
volumes of double-distilled water. Then the mixture was freeze-dried overnight and
49
reconstituted in water for separation on SDS-PAGE (section 3.11).
c) Hydroxylamine cleavage at asn-gly bonds was performed according to Bornstein 
(1970) and Bloxham et al. (1982).
Immediately prior to use, a reaction solution was prepared as follows: 1.8M 
hydroxylamine (3.48g) and 5.3M guanidine-HCl (14.32g) were dissolved in 13ml of 
water in an ice bath. 2.5ml of 12.5N NaOH was added slowly with vigorous stirring, 
followed by the addition of 5 ml of 1M K 2CO3 . The pH of the solution was adjusted 
to 10.5 with additional NaOH and the volume was adjusted to 25ml.
1 volume of PHCS (10.6mg/ml) was mixed with 4 volumes of reaction solution 
and the mixture was incubated at 45°C. Aliquots was taken after incubation times of 
7h, 14h, and 24h. The samples were immediately dialysed at 4°C overnight against 
50mM tris-HCl, pH 8.0, containing 0.1% (w/v) SDS after which they were stored at 
-20°C for running in SDS-PAGE (section 3.11).
3-9 PREPARATION OF MAb-IMMUROSORBENT COLUMN
0.5g of cyanogen bromide activated sepharose-4B were swelled for 30min in 10ml 
of 1M HC1 at room temperature and were then packed into a column of 1.5 ml volume. 
The column was washed with 75ml of 1M HC1 followed by 5ml of 0.2M NaHC0 3 , 
pH 9.5.
Coupling of MAb was performed according to March et al. (1974). 1ml of MAb 
(which has been dialysed against 0.2M NaHC0 3 ,pH 9.5, at 4°C overnight) was added 
into the column (3.3mg MAb/ml of sepharose). Coupling was performed for 20h at 
4°C. The beads were then washed with 5ml of 0.1 M NaHC0 3 ,pH 10, and incubated 
with 2ml of 1% (w/v) casein in 0.2M NaHCC>3 for 18h at 4°C. Beads were washed 
with 10-15ml each of 0.1M sodium acetate,pH4.0, PBS, and 0.2M NaHCC>3 ,pH 9.5. 
Finally, the beads were suspended in PBS containing 0.02% (w/v) azide. The column
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was stored and run at 4°C.
3.10 MAb IMMUNOSORBENT CHROMATOGRAPHY
Fragmented PHCS was reconstituted in PBS. For a column of 1.5ml gel volume, 
300^g of PHCS fragments in 1ml of PBS was loaded, and left to equilibrate in the 
column for 6h. The column was then washed with 15ml each of PBS and 20mM tris- 
HC1, pH 8.0. The bound material was eluted with 3ml of 0.5M NH4OH, pH 10.8, 
and freeze-dried. The freeze-dried eluants were reconstituted in water for analysis by 
SDS-PAGE (section 3-11). The column was re-equilibrated with PBS for storage.
ELECTROPHORESIS AND IMMUNOBLOTTING
3.11 GRADIENT SDS-PAGE
Electrophoresis was performed using the Atto slab gel apparatus with an 
acrylamide gradient of 8-25% on 2mm-thick polyacrylamide gels. A discontinuous tris- 
bicine buffer system containing 0-1% (w/v)SDS, as described by Johnstone and Thorpe 
(1987). The concentration of buffer in the resolving and stacking gels was 0.1 M and 
0.2M in the reservoir buffer.
The resolving gel mixtures were made up according to Table (3-2) and .degased 
prior to addition of SDS and TEMED. 17ml of each gradient mixture was dispensed 
into a linear gradient maker connected to a peristaltic pump. The gel was poured at a 
flow rate of 3-5ml/min using a magnetic stirrer in the 25% (w /v) acrylamide well. 
Delivery to the mould was through a very thin tube pushed to the bottom-centre, of 
the gel and gradually retracted to keep it above the filling gel surface. On completion
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of this, 1ml of water-saturated isobutanol was layered onto the gel and left overnight 
for polymerization, before the stacking gel was loaded.
The resolving gel surface was washed with water. The stacking gel mixture was 
made up according to the recipe in table (32)  and degased prior to the addition of 
SDS and TEMED. Following insertion of the comb into the glass plates, the stacking 
gel was loaded with a pasteur pipette and allowed to set. Once this was performed, the 
comb was removed and the surface of the stacking gel washed with reservoir buffer to 
remove any unpolymerised acrylamide. Then, the gel was transferred to the running 
apparatus, with 400ml of buffer in the bottom chamber, and the whole assembly tilted 
to remove any air bubbles from under the gel. Then another 400ml of buffer was 
poured into the top chamber and the gel pre-run for 20min at 80V, prior to loading 
the samples.
The prepared samples (<100 /d) were loaded into the sample slots, using a 0-100/d 
Hamilton syringe. Electrophoresis was performed at 80V until the sample dye had 
entered the resolving gel, and finally at 100V until the dye front reached the bottom 
of the gel (approximately 12h).
3.12 SAMPLE PREPARATION FOR SDS-PAGE
The sample buffer was prepared by dissolving 1.5 lg  of Tris-HCl and 20ml of 
glycerol in 35ml of water; the pH was adjusted to pH 6.75 with conc. HC1. Then, 4g 
SDS, 10ml 2-mercaptoethol and 4mg bromophenol blue were added and the volume 
made up to 100ml.
Freeze-dried samples were reconstituted with water (10-50/d) and an equal volume 
of sample buffer was added. The mixture was boiled for 2min prior to loading onto 
the gel. Two standard proteins mixtures were used: high molecular weight (/?- 
galactosidase,! 16K; BSA,66K; glyceraldehyde-3-phosphate dehydrogenase,36K; carbonic
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(47.6% : 2.4%) (w/v)
4.8 15.0 1.5
1M Tris, 1 Mbicine (pH 8.2) 3.0 3.0 2.0
water 21.2 8.3 15.3
10% SDS (w /v) 0.3 0.3 0.2
Sucrose (vol.=2.7ml) - 4.5g -
1.5% NH4 persulphate (w/v) 0.7 0.7 1.0
TEMED 10/xl 10/xl 15 M
TOTAL 30 30 20
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anhydrase,29K and trypsin inhibitor,20K) and low molecular weight (Myoglobin,
16.9K; myoglobin "fragment I+II", 14.4K; myoglobin "fragment I", 8 .IK; myoglobin
"fragment II", 6.2K; and myogloblin "fragment III", 2.5K). These were also dissolved
and boiled in the sample buffer, so that 5/d of the molecular weight standard gave
approximately 5/ig of protein per band. Up to 100/d of sample was loaded per track
(0.9mm diameter, 1.8mm depth). From these known mol. wts. proteins standard, a
graph of Logjo%T versus Logio was plotted.
Logjo%T was calculated from the formula:
LcglO ^T = Logjo%[(D x Al% ) + initial gel concentration]
where D: is the distance travelled through the gel,
and Al%  -  change in gel concentration 
gel length
3.13 GEL STAINING
Before staining for protein, the gels were soaked for l-2h  at room temperature 
with several changes of fixing solution [25% (v/v) butanol, 10% (v/v) acetic acid and 
65% (v/v) water]. The gels were then stained by incubation for l-2h in 0.025% (w/v) 
Coomassie blue-R (in 7% (v/v) acetic acid) on a shaker at room temperature.
Destaining was achieved using several changes of destaining solution [7% (w/v) 
acetic acid], until a clear background was obtained on the gels.
3.14 ELECTROPHORETIC TRANSFER OF PROTEINS TO NITROCELLULOSE
The blotting apparatus used was similar to the Bio-Rad T r a n s - B l o t ^ M  but 
had 2 graphite plates (175mm x 222mm x 10mm) as the electrodes.
After running as described in section 3.11 the resolving gel was removed carefully
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from the apparatus and tracks were marked with a scalpel. The gel was rinsed in 
distilled water and washed for 15min in blotting buffer (2mM sodium acetate, 5mM 
MOPS, 20% (v/v) ethanol, pH 7.5). Nitrocellulose sheets (from Schleicher and Schuell, 
with pore size of 0 .2 /un) were cut to the same dimensions as the gel and was soaked 
for lOmin in the blotting buffer. Two sheets of Whatman 3MM filter paper were cut 
and saturated with blotting buffer.
The gel was placed on one sheet of filter paper, on a Bio-Rad Transblot sandwich 
pad, and the nitrocellulose sheet was carefully placed over the gel and covered with 
the second sheet of filter paper. The second sandwich pad was placed over this, and 
the assembled cassette was immersed in a tank containing the blotting buffer, with the 
gel towards the cathode and the nitrocellulose towards the anode. During the assembly 
of these components, care was taken to avoid any air bubbles between successive layers 
of components, since air bubbles will disrupt the elctrical field and alter the pattern of 
protein migration from the gel onto the nitrocellulose sheet. The electrophoretic 
transfer was carried out for 12h at 10 V /6mA, with stirring, and using a water 
cooling coil in the centre of the apparatus.
3.15 AMIDO BLACK STAINING OF NITROCELLULOSE BOUND PROTEINS
Nitrocellulose sheets with blotted protein bands were incubated for 5min with 1% 
(w/v) naphtol blue-black in methanol/acetic acid/water (5:1:4). Destaining was 
performed in methanol/acetic acid/water (5:1:4).
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3.16 IMMUNOBLOTTING OF NITROCELLULOSE BOUND PROTEIN
Following electrophoretic transfer, nitrocellulose strips were incubated for 4-5h at 
room temperature with 1% (w/v) casein in PBS to block non-specific protein binding. 
The strips were kept in separate containers for all further incubations.
The antisera used were diluted 1/50 in 1% (w/v) casein/PBS. 10ml of antibody 
solution were used in each container, and these were incubated for 4h on a shaker at 
room temperature. Strips were washed for 4xl0min in 1% (w /v) casein/PBS and 
incubated with the conjugate (horse radish peroxdase) diluted 1:1000 in 1% (w/v) 
casein/PBS for 2h at room temperature, with shaking. The strips were then washed for 
4x10 min with PBS (azide free).
The colour was developed using: 0.02% (w /v) 3-amino-9-ethylcarbazole, 5% (v/v) 
dimethylformamide, 0.00025% (v/v) thiomersal, 0.03% (v/v) H2O2 in 0.05M sodium 
acetate buffer, pH 5.0, as substrate. Development was continued until distinct bands 
were visible; the reaction was then stopped by washing the strips with water.
3.17 DOT-BLOT IMMUNOSTAIN
Sections of nitrocellulose sheets (40x80mm) were cut, and spotted in duplicate with 
2/xl aliquots of serial dilutions (0.1, 0.2, 1, 10 /xg protein/ml in PBS) of PHCS. After 
drying at 45°C, the nitrocellulose sheets were blocked by incubating at room 
temperature for lh  with 1% (w/v) casein/PBS. The nitrocellulose sheets were then 
incubated with antisera (diluted 1/100 and 1/50 in PBS) at room temperature for 2h. 
Five such nitrocellulose sheets were used, one being incubated with anti-PHCS sera 
(1/100), and two being incubated with anti-peptide PCS-1 sera and anti-peptide PCS-2 
sera of different dilution (1/50 and 1/100). Following this, the subsequent steps for 
the assay were carried out as described above in section 3.16.
56
3.18 CITRATE SYNTHASE ASSAY
Acetyl CoA was prepared by the acetylation of CoA with acetic anhydride, as 
described by Stadtman (1957). lOmg of CoASH (free acid) were dissolved in 1ml of 
water, cooled to 0°C, and 1M KHCO3 (200/d) was added to bring the pH to pH 7.5. 
Then 1M acetic anhydride (100/xl) was added and the mixture allowed to stand for 
lOmin. The acetylation was tested by reaction with 5,5-dithiobis (2-nitrobenzoic acid) 
(DTNB); 10/xl of lOmM DTNB were added to 1ml of buffer solution containing 
20/xl of the acetyl-CoA preparation and the free CoA concentration was calculated 
from the A4 1 2 .
Citrate synthase was assayed spectrophotometrically by the method of Srere et al. 
(1963). All assays were carried out at 25°C. Unless otherwise stated the assay mixture 
contained 20/xl of lOmM acetyl-CoA, 20/xl of lOmM oxaloacetate, 10/xl of lOmM 
DTNB and 10/xl of enzyme solution in a total volume of 1ml of buffer (20mM tris- 
HC1, pH 8.0/1 mM EDTA). The reaction was monitored by measuring the increase in 
absorbance at 412nm due to the reaction of the CoA produced with DTNB (molar 
absorbance coefficient of the thionitrobenzoate at 412nm ■ 13,600 L/mol/cm, at pH
8.0 and 25°C).
a) Effect of anti sera on CS activity
Pure enzyme was diluted, so that a 10/xl sample would give an absorbance change 
of approximately 0.04 units/min in the standard CS assay. 10/xl of samples of such 
enzyme were incubated with a range of concentrations of antisera (anti-peptide sera, 
anti PHCS sera and normal rabbit sera) or of IgG’s of those sera (equivalent to 
0-150/xg of IgG) in 1ml of standard CS assay mixtures lacking oxaloacetate. After 5 
min at 25°C, oxaloacetate was added and the CS activity assayed as normal.
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b) Effect of antisera and protein A
Only the binding of antibodies to determinants at or near the active site is likely 
to affect enzyme activity. However, in order to detect all antibody binding to PHCS, 
regardless of their fine specificity, an insoluble preparation of Staphylaoccus aureus 
protein A was used. This membrane-protein binds IgG via a site in its Fc region and 
so will precipitate all antigen-antibody complexes. Hence such complexes can be 
detected regardless of their effects on CS activity.
Protein A was purchased from Sigma company as insoluble, crude lyophilised cells 
of S. aureus with a quoted binding capacity of 0.061 mg of IgG/mg of solid. Since 
those crude cells have endogenous CS activity, which will affect the assay 
measurements, the insoluble protein A was washed four times in incubating buffer for 
15min that is, until only a negligible amount of CS activity remained. To investigation 
the binding of antisera or IgG’s to CS, method (a) was modified by replacing 300/d of 
the buffer with a suspension of the insoluble protein A (5mg/assay). After standing 
for 30min at 4°C, the tubes were centrifuged for 5min at 2,000g to pellet the 
insoluble protein A -antibody- enzyme complexes and the supernatant was assayed for 
residual CS activity.
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4.1 PREDICTION OF THE EPITOPES OF PHCS
A variety of predictive methods have been used to determine potential antigenic 
and immunogenic peptide sequences of PHCS. Some of these methods are based on 
amino acid sequence and others on crystallographic data. These methods are:
a) Hydrophilicity
This method was first described by Hopp and Woods (1981).
From the solvent parameters of Levitt (1976), each of the 20 amino acids 
commonly found in proteins is assigned a hydrophilicity value. The values used are 
shown in Table 4-1. A hydrophilicity profile is achieved by repetitively averaging 
these values for overlapping sets of 6 residues along the chain and plotting them versus 
the residue number of the leading residue.
The hydrophilicity profile for PHCS was performed by Garforth (1985). In this 
work he adapted a program written in Hewlett-Packard BASIC, for use on a BBC 
micro-computer. The profile obtained is shown in Fig. 4.1.
It can be seen from the results shown in Fig. 4.1 that the top five peaks of 
hydrophilicity occur at residues: 297-302, 323-328, 293-299, 289-294, and 82-87. 
However, it should be noted that, according to Hopp and Woods, only the highest peak 
of hydrophilicity was invariably found to correlate with antigenic sites in the model 
protein system they used (including, swMb; chicken lysozyme; horse heart cytochrome
c). For PHCS, the highest peak of hydrophilicity occurs between residues 297-302.
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b) Composite surface profile
This method was described by Parker et al. (1986).
Each of the 20 amino acids commonly found in proteins was assigned a "surface 
profile value". The surface profile values were arbitrarily assigned on a scale of 0-100, 
and are a composite of HPLC hydrophilicity indices, accessibility and flexibility 
values. A composite surface profile is achieved by repetitively averaging these values 
for overlapping sets of 7 residues along the chain, and plotting them versus the fourth 
residue number of each set of 7.
The composite surface profile for PHCS was performed by Dr. J. M  R. Parker, 
and is shown in Fig. 4-2.
It can be seen that the top five peaks of composite surface profile occur at 
residues: 236-246, 325-332, 78-90, 288-302 and 363-372.
c) Mobility
Use of X-ray crystallography gives not only the precise atomic coordinates, but 
also atomic temperature factor (B values). The temperature factor represents the mean- 
square displacement of each atom, and when plotted against residue number gives a 
graphic image of the degree of mobility existing along the polypeptide chain, as 
described in section 1.3(d).
The B-values obtained for the atoms in PHCS were determined by Remington 
et al. (1982). The mobility profile is shown in Fig. 4.3.
From the results shown in Fig. 4.3, it can be seen that three major peaks of 












120-1 Fig. 4.2 Surface profile for pig heart citrate synthase
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d) Protrusion indices
This method was first proposed by Thornton et al. (1986) and has been described 
in section 1.3(c). Protrusion indices have been calculated for PHCS from its X-ray 
crystallographic atomic coordinates. These PI values are calculated values for each 
amino acid of the PHCS and are a measure of the extent to which a residue protrudes 
out from the surface of the molecule. The data used were provided by Dr. J. M  
Thornton (Birkbeck College, University of London).
Protrusion index profiles were drawn by plotting the PI value of each amino acid 
against its residue number shown in Fig. 4-4.
A further protrusion index profile was obtained by repetitively averaging PI values 
for overlapping sets of 6 residues along the chain and plotting them versus the residue 
number of the last residue in the set. These data are presented in Fig. 4-5, from which 
it can be seen that the most protrusive regions contain residues 288-305, 431-437, 22- 
33, and 194-207.
These data are for the native, dimeric enzyme PHCS. However, it is possible to 
calculate the PI values of each amino acid for one subunit of the enzyme by using the 
same method. But, the protrusive regions found in this case are different from those in 
the dimer, as shown in Table 4-2.
Since this method depends on the shape of the molecule, and the enzyme PHCS 
exists in its native state as a dimer with two identical subunits, therefore the 















Fig. 4.4 Protrusion index profile of PHCS
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Table 4.2 Comparison between the protrusive regions of monomer and dimer enzyme
PHCS
dimer average protrusion monomer average protrusion
288 - 305 8.89 423 - 437 8.95
431 -437 8.75 122 - 137 8.51
22 - 33 8.69 289 -301 8.41
194 -207 8.64 15 - 44 7.10
e) Surface continuousness
This work was first described by Barlow et al. (1986). The method used involves 
centering a sphere of radius 6& on each surface atom of the protein, and calculating 
the proportion (F) of the centres of other surface atoms enclosed by the sphere which 
belong to residues local in the amino acid sequence. Surface atoms were defined as 
those with contact areas > 2A^. Local surface atoms were defined as those ±3 residues 
distant in the sequence of the residues under consideration. Residues which contain no 
surface atoms were assigned a value of F = 0.
The "continuous surface" profile was performed by Dr. J. M  Thornton. These data 
are presented in Fig. 4.6. From these data, using a cut off at 50% "continuousness", it 
was predicted that the most likely continuous antigenic sites would contain residues: 


















Fig. 4.6 Histogram of % continuous surface (F) for residues in PHCS
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f) Conclusion
In this section five different predictive approaches have been applied to compute 
the likely antigenic sites present on PHCS.
The major antigenic sites predicted by each method are shown on Table 4-3. 
Predictions made by methods a, b, c and d all suggest that a region contained within 
residues 288*302 is likely to be an antigenic site. Results from method (e) do not 
predict this region to contain a continuous epitope as residues 288, 290, 291, 294, 
298, 301 and 302 show less than 50% "continuousness". Therefore an epitope is
strongly predicted to occur between residues 288-302, but it is likely to be partly 
discontinuous. One further discontinuous epitope (residues 76-90) is predicted by 
methods a, b and c which is in a different region of the PHCS molecule, as shown in 
Fig. 4.7.
So, in this study these two peptides (288-302 and 76-90) have been synthesised, 
purified and used as both antigens and immunogens as will be discussed in the 
following sections.
4.2 SYNTHESIS OF PEPTIDES
As pointed out in section (4.1), peptides selected for synthesis were those which 
were determined by more than one predictive method and located in distinct regions of 
the surface of the native structure as shown by molecular graphics diagram Fig. 4.7. 
Therefore two peptides have been selected of 15 amino acid residues each: (PCS-1) 
which represented the peptide at region 288-302 and (PCS-2) representing the peptide 
at region 76-90. The sequences of these peptides are shown in Fig. 4.8. Peptides were 
synthesised as described in section 3.3 by the solid-phase method using Fmoc protecting 
groups. Peptide PCS-1 was synthesised, starting from the Car boxy-terminal
71
Table 4.3 Summary of the predicted epitopes of PHCS































leu - gin -
The sequences of peptides PCS-1 and PCS-2
PCS-1 (288-302)
302
- glu - val - gly - lys -  asp -  val - ser -  asp -  glu - lys - leu -arg
PCS-2 (76-90)
76 90
lys - met - leu - pro - lys - ala - lys -  gly - gly - glu - glu - pro - leu - pro -glu
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amino acid arg (residue no. 302) backward to the amino acid (no. 288) leu. Also,
PCS-2 was synthesised from the amino acid residue no. 90 (glu) backward to residue 
no. 76 (lys). After each amino acid residue was added to the growing peptide, a colour 
test was performed to confirm the coupling efficiency, while amino acid analysis was 
performed at the completion of each synthesis.
4.3 PURIFICATION OF SYNTHETIC PEPTIDES
After the two peptides had been synthesised, the purity of each peptide was 
assessed by HPLC as described in section 3.5. Samples from each peptides were 
analysed by HPLC at a concentration of 1 mg/ml (in 5% acetonitrile). Fig. 4.9 shows a 
distinct and clear peak corresponding to pure peptide. Furthermore, purity of peptides 
was also identified using chromatography on the Pharmacia FPLC system, as described 
in section 3.5. After desalting the synthetic peptides through a column at Biol Gel P2 
as explained in section 3-5, the peptides were dissolved in lOmM NaAc 
pH 5.0 and injected through a 500/d loop to the FPLC system containing a Mono S 
anion exchange column. The bound peptide was then eluted with an 0.5M NaCl 
gradient. After the end of the run, fractions corresponding to peptide peak as shown 
in Fig. 4.10 were pooled and freeze-dried overnight. The pure peptides were stored at 
-20°C.
4.4 AMINO ACID ANALYSIS
Amino acid analysis as described in section 3.4 was determined for samples of 
both peptides at the completion of synthesis. Samples in duplicate were hydrolysed in 
6M HC1, in evacuated tubes at 110°C for 24h and 48h. Then, the solution was 
evaporated to dryness and the residue reconstituted in amino acid analysis buffer
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Peptides PCS-1 and PCS-2 analysed by HPLC as described in the text
Column C l 8 reverse phase
G radient 5% - 95% acetonitrile in water















(25mM HC1) for analysis on an ion exchange amino acid analyzer using pH gradient 
elution. Samples were compared with standards for calculation of absolute levels of 
each amino acid. The results of analysis of samples of both peptides seem acceptable 
when compared with theoretical residues numbers. Table 4.4 shows the experimental 
results and theoretical composition for peptide PCS-1 at region 288-302, while Table
4.5 shows the results of peptide PCS-2 at region 76-90.
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Table 4.4 Amino acid analysis of peptide PCS-1 at region (288-302)











Table 4.5 Amino acid analysis of peptide PCS-2 at region (76-90)
residues amino acid composition
experimental theoretical
Ala 1.0 1
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Polyclonal and monoclonal antibodies have been raised against intact PHCS in 
previous work in this laboratory (Brennand, 1987). All antisera were evaluated for 
their ability to react with intact PHCS and some of them with fragments of PHCS. 
Using a number of ELISA systems, the MAb’s that were tested were all able to 
interact with intact PHCS to varying degrees.
5.2 REACTIVITY OF ANTISERA AND MAb’s WITH INTACT PHCS
Reactivity of antisera and MAb’s were tested against intact PHCS. Mouse anti- 
PHCS was used at dilutions in the range 1/20 - 1/10^ and MAb’s were used at 
concentrations in the range 0.01-50 /ig/ml.
The sandwich ELISA as described in section 3.7b, in which antigen was 
immobilized via polyclonal rabbit anti-PHCS, was used. The results are plotted as 
A405  versus dilution of antibody. Fig. 5.1 shows that the binding of mouse anti-PHCS 
sera to intact PHCS varies linearly with dilution in the range 1/20 - 1/250, and 
significant binding could be detected at antiserum dilutions up to 1/1000. Normal 
mouse serum binding was significantly less than the binding of mouse anti-PHCS sera 
in this region.
As shown in Fig. 5.2, the reactivity of MAb’s B and C with intact PHCS 
resembled that of anti-PHCS serum (Fig. 5.1). There was no significant difference 
between the binding of MAb’s B and C.
An identical pattern was obtained Fig. 5.3 when the direct coating assay used, as 
described in section 3.7a. Both MAb’s (B, C) gave reactivities consistent with those 
obtained by the sandwich assay.
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Fig. 5.1 D ilution curve o f mouse anti-PHCS serum in sandwich ELISA 
Substrate incubation was for lh .
Each point represents the mean o f duplicate determ inations. 
( a ) mouse anti-PHCS serum, (□ )  normal mouse serum.
1.5
1.0
D ilution of antibody
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Fig. 5.2 D ilution curves for MAbs in sandwich ELISA 
Substrate incubation was for lh .
(■ ) MAb B, ( • )  MAb C, (□ )  normal mouse IgG.
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Fig. 5.3 D ilution curves for MAbs in direct ELISA 
Substrate incubation was for 1 h. (■ )
MAb B, ( • )  MAb C, ( o )  norm al mouse IgG. Each 
point represents the mean o f duplicate determinations.
O rO
A ntibody concentration (/ig/m l)
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5.3 INHIBITION OF ANTI PHCS SERA BY SOLUBLE PHCS
This assay was performed using the competitive ELISA as described in section 
3.7c. A range of concentrations of PHCS (0-50 /ig/ml) was used as competitor while 
the concentration of antibody used was fixed (1/100). Normal mouse serum was used 
as a control. Antibody activity in the presence of soluble PHCS was expressed as 
percentage of the activity measured in the absence of competitor. The relationship 
between the percentage of activity versus the competing antigen added is shown in Fig. 
5.4; it can be seen that at a concentration of competing antigen of 50 /ig/ml, the 
antibody binding was inhibited by 80%.
5.4 DIRECT ELISA USING SYNTHETIC PEPTIDE
The synthetic peptide PCS-1 at the range of concentrations 1, 2, 5, 10 /ig/ml were 
used to determine the optimum plate coating concentration for the direct ELISA 
method. MAb E was used for optimization of plate coating, to define conditions for 
use with others MAb’s. The plate was then exposed to a range of dilutions of MAb E, 
with normal mouse-IgG as control. The results obtained are shown in Fig. 5.5 as a 
graph of A405  versus the dilution of antibody. There was no significant difference 
between the dilution curves when different concentrations of peptide were used for 








Fig. 5.4 Com petitive sandwich ELISA
100% activ ity  represents A 4 0 5  = 1.55.
Substrate incubation was for lh .
( a ) anti-PHCS, (□ ) normal mouse serum. Each point 
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Fig. 5.5 Determ ination of optimum plate coating concentration 
fo r PCS-1 in direct ELISA
Substrate incubation was for 40min. (□ ) normal mouse serum. 
Each point represents the mean of duplicate determ inations.
p e p t i d e  c o n c e n t r a t i o n  
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5.5 COMPARISON BETWEEN REACTIVITIES OF POLYCLONAL AND 
MONOCLONAL ANTIBODIES WITH INTACT PHCS AND PEPTIDE
The reactivities of polyclonal anti-PHCS and MAb against PHCS and peptide PCS-
I were investigated using the direct ELISA method. The plates were coated with intact 
PHCS or peptide PCS-1 and were then exposed to a range of dilutions (0.5, 5,
50 /ig/ml) of rabbit anti PHCS (polyclonal) and mouse-anti PHCS (MAb B). Normal 
rabbit-IgG and mouse IgG were used as controls. The results obtained are shown in 
Fig. 5.6 for polyclonal anti serum against intact PHCS and PCS-1, and in Fig. 5.7 for 
MAb B against both antigens. These results indicate that both MAb B and polyclonal 
anti-PHCS showed higher reactivity with intact PHCS than with peptide PCS-1.
5.6 REACTIVITY OF MAb’s WITH SYNTHETIC PEPTIDES
As pointed out in section 5.1, in previous work by Brennand (1987) a library of
II mouse monoclonal antibodies have been produced, using PHCS as immunogen. In 
the present work, the reactivity of each MAb with both synthetic peptides PCS-1 and 
PCS-2 has been examined using the direct ELISA method.
Peptides were immobilized on the solid phase for 18 h at 4°C, and then the plates 
were blocked with 1% (w /v) casein in PBS before exposure to MAb’s. Absorbance 
values were plotted against antibody dilution. Fig. 5.8 shows the results when peptide 
PCS-1 was used as antigen, while Fig. 5.9 shows the results using PCS-2. The 
experiment was repeated twice. From these figures it can be seen that different MAb’s 
show varying degrees of reactivity with each peptide. In the case of peptide PCS-1 
(Fig. 5.8), the order of reactivity of MAb’s is M>D>E>K>B>C>F>A>G>H>L, while 
with peptide PCS-2, (Fig. 5.9), the order of reactivity was slightly different (M>E> 
D>K>B>C>G>F>A>H>L). However, all reactions of MAb’s with PCS-1 are greater 
than that with peptide PCS-2 except for MAbs E and G, as shown in Table 5.1.
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Fig. 5.6 Comparison between reactivities o f anti-PHCS w ith 
intact PHCS and PCS-1 in direct ELISA 
Substrate incubation was for 30min.
( a ) anti-PHCS w ith CS, ( • )  anti-PH CS with PCS-1, 
(□ )  normal rabbit IgG w ith CS, ( * )  normal rabbit 
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Fig. 5.7 Com parison between reactivities of MAb "B" w ith 
in tact PHCS and PCS-1 in direct ELISA 
Substrate incubation was for 70min.
( a ) MAb with CS, (o )  MAb w ith PCS-1, (□ ) norm al 
mouse IgG w ith CS, (* )  normal mouse IgG w ith PCS-1. 
Each point represents the mean of duplicate determ inations.
1.2
OJ50 0.55
A ntibody concentration (/ig/m l)
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Fig. 5.8 R eactivity  o f MAbs with PCS-1 in direct ELISA 
Substrate incubation was for lh .
Results for MAbs M ,D,E,K,B,C are indicated on 
the diagram. (--) region represents the results 
for MAbs F,A ,G ,H ,L. (□ ) represents normal mouse IgG. 
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Fig. 5.9 R eactivity  of MAbs w ith PCS-2 in direct ELISA 
Substrate incubation was for lh .
Results for MAbs M ,E,D,K,B,C are indicated on the diagram. 
(- -) region represents the results for MAbs G ,F,A ,H ,L- 
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Table 5.1 Activity of MAb’s with synthetic peptides 















To examine the specificity of reaction of MAb’s with peptides PCS-1 and PCS-2, a 
peptide (x-peptide) of 10 amino acid residues whose sequence is unrelated to the 
sequence of PHCS, has been chosen and used as a control peptide for the reaction. 
From the data explained above (Fig. 5.8 and 5.9), two different MAb’s were selected 
(M and B) for use in this assay. The assay was carried out as described above, but it 
included a plate coated with 1 /ig/ml of x-peptide as control. The results obtained are 
shown in Fig. 5.10. Both MAb’s M and B showed reactivity with peptides PCS-1 and 
PCS-2 (similar to their reactivity as shown in Figs. 5.8 and 5.9) but also with x- 
peptide.
5.7 INHIBITION OF MAb B BY SOLUBLE PEPTIDE
Brennand (1987) found that MAb B could bind to intact PHCS and suggested that 
it bound to a site in the region 258-313. Since in this study, two different peptides 
have been synthesised chemically, corresponding to residues 288-302 for peptide PCS-1 
and residues 76-90 for peptide PCS-2, inhibition of MAb "B" by both peptides was 
examined using competitive ELISA, as described in section 3.7c. In this assay, antibody 
was reacted with peptide in solution prior to assessment of antibody binding to intact 
PHCS on the solid phase. MAb B, at a fixed concentration (20 /xg/ml), was incubated 
with varying concentrations of peptides (0.1, 1, 10, 100 /xg/ml) for lh  at 37°C, and 
was then exposed to PHCS-coated plates. By plotting % inhibition of binding versus 
competing antigen (peptide) added, as shown in Fig. 5.11, it can be seen that peptide 
PCS-1 inhibited the reaction by up to 13%, while PCS-2 showed no effect.
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Fig. 5.10 Reactivity of MAbs M and B w ith PCS-1, PCS-2 
and x-peptide in direct ELISA 
Substrate incubation was 75min.
(a ,a ,*) MAb M with PCS-1, PCS-2, x-peptide respectively.
( •  , 0 , • )  MAb B w ith PCS-1. PCS-2, x-peptide respectively.











Fig. 5.11 Inhibition o f MAb B by soluble PCS-1 and PCS-2 in 
com petitive direct ELISA 
Substratet incubation was for 45min.
(■ ) MAb B w ith PCS-1, (□ )  w ith PCS-2, (-•-) normal 







5.8 INHIBITION OF MAb B BY SOLUBLE PHCS
In this assay, the competitive ELISA method was used as described in the previous 
section 5.7. MAb B, at a fixed concentration (10 /ig/ml), was incubated with varying 
concentrations of competiting antigen (PHCS) 5, 15, 25, 50, 100 pg/ml for lh  at 
37°C prior to exposure to a PHCS-coated plate.
The results obtained, plotted as the relationship between % activity and
competiting antigen (PHCS) added, are shown in Fig. 5.12. It can be seen that PHCS 
inhibited the reaction of MAb B against PHCS by up to 16%.
5.9 FRAGMENTATION OF PHCS
a) by mild acid
PHCS was cleaved at asp-pro bonds by using mild acid (15 mM HC1), as described
in section 3.8a. After hydrolysis for 90 min at 110°C, the products were separated by
electrophoresis on an 8-25% (w /v) polyacrylamide gel, using the tris-bicine buffer 
system as described in section 3.11.
Complete hydrolysis yielded 5 peptides detectable on the stained gel (Fig. 5.13). A 
graph of Logjo%T against Logjo mol.wt. was plotted for the mol.wt. standards (Fig. 
5.14). For each fragment produced following the cleavage, Logjo%T values were 
calculated from the distance travelled throughout the gel, and the corresponding
mol.wts. were determined from the graph (Fig. 5.13). So, the mol.wts. of the peptides 
were: 4.9K, 8.7K, 13K, 17.5K and 21.3K.
Since the amino acid sequence of PHCS contains 4 asp-pro bonds [Fig. (2.2) page 
(27)] a complete and specific hydrolysis at asp-pro would yield 5 products containing 
residues 1-59, 60-257, 258-327, 328-344 and 345-437. The expected mol. wts. of the 







Fig. 5.12 Inhibition of MAb by soluble PHCS in com petitive 
direct ELISA
Substrate incubation was for 30min.
(■ ) MAb B, (-•-) normal mouse IgG. Each point 
represents the mean of duplicate determ inations.
100
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Fig. 5.13 Cleavage of PHCS at asp-pro bonds by dilute acid, shown on 8-25% 
SDS-PAGE
1 2 3 4 5
Track 1; Standards: 66k, 45K , 36K , 29K  and 20K . 
T rack 2; Standards: 17K, 14.4K, 8 .2K , 6.2K and 2.5K. 









Fig. 5.14 logm  nmol, wt. versus log%T for the molecular weight standards 
shown in Fig. 5.13
(■ ) High mol. wt. standard, (□ ) Low mol. wt. standard.





acids, as shown in Table 5.2.
Comparison of the observed mol. wts. of fragments produced by mild acid cleavage 
with the predicted values shown in Table 52  suggests that complete cleavage of all 
asp-pro bonds was not obtained.
b) By CNBr
Fragmentation of PHCS at met residues using CNBr was achieved as described in 
section 3.8b. The products of the fragmented PHCS were separated by electrophoresis 
on an 8-25% (w /v) polyacrylamide gel using the tris-bicine buffer system as described 
in section 3.11. Four major peptides fragments were observed on the gel, (Fig. 5.15).
Plotting Log jo  mol.wt. versus log]o%T for mol. wt. markers, (Fig. 5.16), the mol. 
wt. of each fragment could be measured. The bands corresponded to mol. wts. 15.8K, 
10K, 5.5K and 1.8K respectively. Theoretically, since it contains 15 met residues, 
PHCS fragmented by CNBr should yield 16 fragments with the mol. wts. listed in 
table 5-3.
We would not expect to see all 16 bands on the gel, because some fragments have 
similar mol. wts. and would not be resolved, and some are too small and would be lost 
from the gel. Therefore, we would expect to observe fragments of mol. w tj 9.6K, 6 K, 
4.9K or 4.5k and 2k.
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Table 5.2 Theoretical products formed by cleavage of PHCS at asp-pro bonds
Molecular weights of fragments containing amino acid
1-59 60-257 258-327 328-344 345^37
48969 48969 48969 48969 48969
38500 42500 42500 42500 42500
36400 38500 38500 38500 20300
28700 36400 36400 32000 12600







Fig. 5.15 Cleavage of PHCS at met residue by CNBr, shown on 8-25% SDS-PAGE
1 2  3 4
Track 1; Standards: 66k, 45K , 36K , 29K  and 20K. 
T rack 2; Standards: 17K, 14.4K, 8 .2K , 6.2K  and 2.5K. 
Track 3; undigested PHCS.





Fig. 5.16 log io  mol, wt. versus log%T for the molecular weight standards 
shown in Fig. 5.15
(■ ) High mol. wt. standard, (□ ) Low mol. wt. standard.







Table 5.3 Theoretical products formed by fragmentation of PHCS by CNBr
no. frag. size M  Wt.
1 M O 40 4800
2 41 1 *<
3 42-45 4 <
4 46-48 3 <
5 49-77 29 3480
6 78-127 50 6000
7 128-138 11 <
8 139-176 38 4560
9 177-216 50 6000
10 217-228 12 <
11 229-266 38 4560
12 267-346 80 9600
13 347-387 41 4920
14 388-390 3 <
15 391-425 35 4200
16 426-437 12 <
* less than 1.5K.
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c) By hydroxylamine
PHCS was cleaved at asn-gly bonds using hydroxylamine as described in section 
3.8c. The products of the fragmented enzyme were separated by electrophoresis on an 
8-25% (w /v) polyacrylamide gel, using the tris-bicine buffer system. The cleaved 
PHCS yielded 3 bands, although on the photograph of the gel (Fig. 5.17) only one 
major band can be observed, while the other two bands are not visible clearly. 
Determination of the mol. wt. of those bands indicated that one of them corresponded 
to intact PHCS (about 49K) while the others had molecular weights of 29K and 18K 
respectively.
As mentioned above, hydroxylamine should cleave PHCS at asn-gly bonds, and 
according to the sequence of PHCS, Fig. (2.2) page (27), the cleavage should occur at 
region 267-268 forming two major fragment corresponding to regions 1-267 and 268- 
437. (mol. wts. = 30K & 19K, respectively).
5-10 MAb IMMUNOSORBENT CHROMATOGRAPHY OF CNBr DIGESTED 
PHCS
A sample of PHCS (300 /ig), cleaved with CNBr, was loaded onto a 1.5 ml 
column of Sepharose 4B-MAb B immunosorbent prepared as described in section 3.9. 
Chromatography was performed as described in section (3-10). The Column was 
washed with 15ml each of PBS, 20mM tris-HCl buffer, pH 8.0, and finally with 3ml 
of 0.5M NH4OH. The NH4OH wash should contain bound peptide eluted from the 
column as un-bound peptide should have been eluted in the previous washes. After 
freeze-drying the NH4OH eluate, the product was reconstituted in H 2O and run on 8 - 
25% (w /v) polyacrylamide gels, using tris-bicine buffer as described in section 3.11.
The band pattern obtained is shown in Fig. 5.18. The bands observed in the track
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Fig. 5.17 Cleavage of PHCS at asn-gly bonds by hydroxylam ine, shown on 8-25% 
SDS-PAGE
1 2 3 4 5 6
T rack 1; undigested PHCS.
T rack 2; Standards: 66K , 45K , 36K , 29K  and 20K . 
T rack 3,5; standards, 17K, 14.4K, 8.2K , 6.2K and 2.5K. 
T rack 4,6; hydroxylamine-digested PHCS.
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loaded with the peptide eluted from the column with NH4OH seem analogous to those 
bands appearing in the track loaded with a sample of fragmented PHCS.
According to these results, two assumptions can be made. It could be that the MAb 
is not specific for any one of these CNBr peptide fragments, or alternatively, it could 
be some protein was released from the column in this NH4OH fraction.
These possibilities were tested by repeating the run and using a blank (PBS) 
instead of digested enzyme, to check if  there was any MAb relased from the column. 
From the band pattern shown in Fig. 5.19, it can be seen that there is no band 
observed in track from the blank fraction, which means that there was no protein 
relased from the column by the NH4OH wash. Therefore, although fragmentation of 
PHCS by using CNBr yielded fragments, no single fragment was specifically bound to 
MAb BnSepharose.
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Fig. 5.18 A ffin ity  chrom atography o f CNBr-digested PHCS on MAb B column. 
Separation o f products on 8-25% SDS-PAGE
1 2  3 4 5
T rack 1; undigested PHCS.
Track 2; Standards: 6 6 K , 45K , 36K , 29K  and 20K . 
T rack 3; CNBr-digested PHCS.
T rack 4; Standards: 17K, 14.4K, 8.2K , 6.2K  and 2.5K. 
T rack 5; m aterial eluted in N H 4 OH fraction.
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Fig. 5.19 A ffin ity  chrom atography on MAb B column, blank control. 
Separation o f products on 8-25% SDS4PAGE
1 2 3 4 5 6
Track 1; undigested PHCS.
Track 2; Standards: 6 6 k, 45K , 36K , 29K  and 20K. 
Track 3,5; CNBr-digested PHCS.
Track 4; Standards; 17K, 14.4K, 8 .2K , 6.2K and 2.5K. 
Track 6 ; Blank (PBS eluted in N H 4 OH fraction).
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5.11 DISCUSSION
A number of ELISA systems have been used to investigate the reactivity of 
polyclonal and MAb’s raised against the enzyme PHCS. Intact PHCS and synthetic 
peptides corresponding to specific regions of the sequence of PHCS were used as 
antigens in these ELISAs.
In the sandwich ELISA technique, antigen is immobilized to polyclonal antibody- 
coated solid phase. The results obtained from this assay show that mouse anti-PHCS 
sera gave a strong cross-reactivity, particularly in the range of dilutions between 1 /20  
- 1/250 with intact PHCS, and significant binding could be evaluated at anti-sera 
dilutions up to 1/1000. On the other hand, normal mouse serum showed a very weak 
response compared with mouse-anti-PHCS serum.
Thus, both MAbs showed a significant interaction with PHCS in the sandwich 
ELISA, the immobilization method via the polyclonal antibody probably ensuring that 
the enzyme is presented in its native conformation. This interaction with native PHCS 
is consistent with our observations that the enzyme is effective in its soluble form in 
competitive ELISA assays, whereas in ELISA method where the PHCS-coating is direct 
with the plate, the enzyme maybe partially denatured.
Synthetic peptide PCS-1 has been used as the immobilized antigen at various 
concentrations (1, 2, 5 and 10 /Jg/ml) in the direct ELISA to determine the optimum 
concentration which should be applicable for coating. For this purpose, MAb E was 
used to define the conditions with other MAbs. The results of this assay indicate that 
there is no significant variation between the interaction of MAb E with the different 
peptide coated-concentrations. Therefore, for reasons of economy, peptide at 1 /xg/ml 
was chosen for use in the following assays.
As mentioned earlier in section 5.1, a library of 11 monoclonal antibodies has been 
previously produced against intact PHCS. All of these MAb’s were evaluated for their 
ability to interact with the synthetic peptides PCS-1 and PCS-2 in this study, using
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the direct ELISA. The results obtained from this assay showed that the MAb’s 
displayed varying degrees of interaction with both peptides. In the case of peptide 
PCS-1, the order of reactivity of these MAb’s is: M>D>E>K>B>C>F>A>G>H>L. In 
the case of PCS-2 the order of reactivity slightly was different from that with PCS-1. 
MAb M gave the highest reactivity with both peptides, so, its value at 50 /ig/ml was 
taken as 100% activity and the relative percentage activities of all others MAb were 
calculated with respect to it, (Table 5.1). From that table, it can be seen that most 
MAb’s show a higher reactivity with peptide PCS-1 than with PCS-2, although some 
of them show a weak reactivity with both peptides.
The MAb’s thus reacted with both peptides, although these peptides are at 
different regions of PHCS molecules as pointed out in section 4.3. Therefore, to 
investigate the specificity of reaction of the MAb’s with these peptides, a random 
peptide (x-peptide) of 10 amino acid residues (cys-met-val-glu-arg-tyr-val-arg-pro-cys) 
was selected for use as a control for the ELISA reaction. Two MAb’s were used for 
the assay, MAb M (which showed the highest reactivity with both peptides) and MAb 
B. It appears from the results obtained that MAb’s M and B reacted with both peptides 
(PCS-1 and PCS-2) as expected from the previous data, but they also reacted with x- 
peptide, albeit to a lesser degree. This suggests that some of the observed MAb-binding 
to immobilized peptides may be an artifact of the assay system.
The direct ELISA method has also been used, to compare the reactions of 
polyclonal and monoclonal antibodies with intact PHCS and synthetic peptide PCS-1. 
MAb B and rabbit anti-PHCS were used and it was found, for both antibodies, the 
reaction with intact PHCS was stronger than with peptide.
The binding of anti-PHCS serum to intact PHCS was investigated using the 
competitive ELISA method. The native PHCS was used as a competitor at varying 
concentrations, and was incubated with a fixed dilution of anti-PHCS sera prior to 
exposure to the antigen (PHCS)-coated solid phase. It was found that the binding of 
anti-PHCS sera to immobilized PHCS is inhibited by 80% by soluble PHCS. Using the
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same ELISA technique, MAb B was inhibited by soluble intact PHCS by 
approximately 16%.
The binding of MAb B to immobilized PHCS has also been examined for 
inhibition by soluble synthetic peptides PCS-1 and PCS-2 using the competitive ELISA 
method. It was found that MAb B is slightly inhibited by PCS-1 (up to 13% 
inhibition), while PCS-2 had no effect on the MAb binding.
The enzyme PHCS was chemically fragmented at specific sites by a variety of 
reagents: mild acid (15 mM HC1), hydroxylamine and CNBr.
In the case of mild acid, PHCS should be selectively cleaved at asp-pro bonds. 
After incubation of the PHCS for 90 min in mild acid, five major fragments were 
found of mol. w ts .: 4.9K, 8.7K, 13K, 17.5K and 21.3K.
PHCS has 4 asp-pro bonds in its sequence and therefore complete cleavage should 
give 5 fragments with molecular weights; 2.1 K, 6.5K, 7.7K, 10.5K and 22.2K.
From the data above, it can be concluded that complete cleavage at asp-pro bonds 
was not achieved, as shown by comparison between the mol.wt. values of the two sets 
of fragments (experimentally produced and predicted).
Hydroxylamine cleaves at asn-gly bonds. Treatment of PHCS produced 3 fragments 
corresponding to the native enzyme with mol.wt. approximately 49K and the two 
peptides of mol.wt. 29K and 18K.
In the sequence of the PHCS, there is only one asn-gly bond (267-268). Therefore, 
theoretically two major fragment should formed one at region 1-267 of mol.wt.~30K 
and the other at region 268-437 of mol.wt.-19K. The results obtained from the data 
above indicate that the mol.wt. of fragments produced experimentally using 
hydroxylamine corresponded to those predicted from the sequence.
CNBr cleaves at met residues. After digestion of PHCS by CNBr, 4 major 
fragments were produced with mol.wts. : 15.8K, 10K, 5.5K and 1.8K respectively.
From Table 5.3 it can be seen, that according to the amino acid sequence of PHCS 
molecule of 437 residues, there are 15 met residues exists. Therefore, it would be
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expected to yield 16 fragments when digested by CNBr as listed in the table above.
Not all these fragments could be observed when the digested enzyme was separated by 
gel electrophoresis, due to the fact that some of them are very small and some have 
similar mol.wts. The major bands which could be detected were 9.6K, 6K , 4.5K and 
2K.
Since the fragments of PHCS produced by mild acid and hydroxylamine were 
studied in previous work for their binding to MAb’s B and C by using immunoblot 
technique. Therefore, in this study the CNBr-fragments of PHCS have been examined 
for their ability to bind MAb B by using the immunosorbent chromatography 
technique. More information will be presented in the next chapter (section 6.9), about 
the immunobloting of these fragments with antisera to synthetic peptides and anti- 
PHCS serum. However, a MAb B immunosorbent column was used and from the 
results obtained, it can be seen that there is no significant difference between the band 
pattern detected in the track loaded with the peptide eluted from the column with 
NH4 OH and those bands observed in the track loaded with fragmented PHCS. This 
means, that MAb B might not be specific for any one of these fragments, thus no 
single peptide was retained specifically in the column by binding to the MAb. An 
alternative possibility that protein was released from the column was studied by using 
a blank (PBS) instead of the digested PHCS sample. The failure to detect any band in 
the track loaded from the blank fraction indicates that there was no protein released 
from the column by the NH4OH wash. So, it can be concluded that no single 
fragment was specifically bound to MAb B-Sepharose.
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Polyclonal antibodies have been raised to synthetic peptides PCS-1 and PCS-2, 
which correspond to regions of the PHCS molecule between residues 288-302 and 
76-90, respectively. Rabbits were immunized with these peptides after conjugation to a 
carrier (KLH) as described in section 3.6. Then antibodies produced were detected in 
serum samples using ELISA techniques.
6.2 DETECTION OF ANTIBODIES IN ANTI-PEPTIDE SERA
As described in section 3.6, for each immunizing peptide two rabbits were used 
and bled after each boosting injection. Five samples were taken from each animal in 
total. The direct ELISA was used to detect and compare the antibody levels in serum 
samples. EIA plates were coated with peptide PCS-1 or PCS-2 (1 /ig/ml) and the 
assays were carried out as described in section 3.7a. Plotting the absorbance at 
405 nm versus serum dilution, the results obtained are shown in Fig. 6.1 and Fig. 6.2.
It can be seen from Fig. 6.1 and Fig. 6.2, with an increased number of booster 
injections, the level of serum antibody against peptide antigen increased and reached its 
highest level in bleed number five. The patterns were similar for the antisera from 
both rabbits immunized with the same immunogen. Therefore, antisera from the fifth 
bleed were used in all the following assays.
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F ig .  6.1 D i l u t i o n  curves  o f  anti-PCS-1 sera  using d i r e c t  ELISA 
R e su l t s  from b le ed s  1-5 are i n d ica te d  on the f i g u r e s
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6.3 SPECIFICITY OF ANTI-PEPTIDE SERA
The specificity of anti-peptide sera was determined by using the ELISA technique. 
Samples of both synthetic peptides PCS-1 and PCS-2 were used as antigens in the 
direct ELISA, and these were incubated with a range of dilutions of anti-peptide 
serum, anti-KLH (carrier) sera, or normal rabbit serum as control. Following 
incubation with antibody enzyme-conjugate (alkaline phosphotase), substrate was added 
and the resulting absorbance at 405 nm measured.
Plots of A405 against serum dilution are shown in Fig. 6.3 and Fig. 6.4 for
peptide PCS-1 and PCS-2, respectively. Fig. 6.3 indicates that only antibodies raised
against peptide PCS-1 reacted with peptide PCS-1, while the others antibodies, raised
against peptide PCS-2 and carrier (KLH), did not show reactivity with the PCS-1-
coated plate. Furthermore, normal rabbit serum, which was used as a control, gave no 
reaction.
Fig. 6.4 shows the reactivity of anti-PCS-2 with peptide PCS-2-coated plate, while 
the other antibodies (anti-PCS-1, anti-KLH and normal rabbit serum) did not react 
with peptide PCS-2. From Fig. 6.3 and Fig. 6.4 it can be seen that antibodies from 
both rabbits which were immunized with the same immunogen showed similar 
reactivity.
Both antibodies (anti-peptide PCS-1 and anti-peptide PCS-2) gave a positive 
reaction, when incubated with the intact enzyme PHCS, as shown in Fig. 6-5. In this 
case, PHCS was used as an antigen, and was immobilized on the plate before exposure 
to the antibodies. The pattern shown in Fig. 6.5 indicates that anti-PHCS gave a 
higher reactivity with PHCS than anti PCS-1 or anti PCS-2, although anti PCS-1 
showed higher reactivity than anti-PCS-2. The pattern was similar for both rabbits 
immunized with the same immunogen.
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Fig. 6.3 Specificity of anti-peptide sera in direct ELISA against PCS-1 
Substrate incubattion was for 45min.
( •  , o )  anti-PCS-1 in both rabbits, ( ■ ) anti PCS-2, ( ▼ ) an ti-  K L H , ( □ ) 
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Fig. 6.4 Specificity of anti-peptide sera in direct ELISA against PCS-2 
Substrate incubation was for 45min.
( ■ , □ ) anti PCS-2 in both rabbits, ( •  ) anti-PCS-1, ( o  ) an ti-K L H , ( y ) 







Fig. 6.5 D ilution curves for anti-PHCS and anti-peptide sera in direct ELISA against PHCS 
Substrate incubation was for lh .
( • )  anti-PHCS, ( a , a )  anti-PCS-1, (□ ,■ )  anti-PCS-2, ( * )  anti-K LH ,














6.4 REACTIVITY OF ANTI-PEPTIDE SERA WITH EXTENDED PEPTIDE
Peptides PCS-1 and PCS-2 were both extended with two amino acid residues (gly 
and cys) for coupling to carrier for immunizing, as described in section 3.6. Therefore, 
the extended peptides (PCS1-GC and PCS2-GC) were used to examine their interaction 
with anti-PCS-1 and anti-PCS-2 sera using the direct ELISA technique. The plates 
were coated with the antigens PCS-1, PCS1-GC, PCS-2 and PCS2-GC at 1/ig/ml and 
then were exposed to either anti PCS-1 or anti PCS-2 at a series of dilutions. After 
that, assays were carried out as described in section 3-7a.
The results obtained are shown in Fig. 6-6  and Fig. 6-7. The results show that the 
anti-peptide sera react with the corresponding peptide in either extended or non­
extended form.
That is, anti peptide PCS-1 sera reacted with both PCS-1 and PCS1-GC but not 
with PCS-2 and PCS2-GC and vice versa. Both anti PCS-1 and anti PCS-2 showed 
higher reactivity with their extended peptides than with the corresponding non­
extended peptide.
6.5 INHIBITION OF ANTI-PEPTIDE SERA BY PEPTIDES
Inhibition by peptide of anti-peptide serum binding to solid-phase antigen was 
examined using the competitive ELISA technique. The anti-peptide serum at a fixed 
dilution (1:100) was incubated with varying concentrations of peptide (0, 0.1, 0.5, 1, 
5 and 10 ng/m\) for 1 h at 37°C prior to transfer to the wells of plate coated with 
PHCS. Then the assay was continued as described in section 3.7.
Plotting the percentage of anti-peptide bound versus the competing antigen added 
gave the results shown in Fig. 6.8 and 6.9. From Fig. 6.8 it can be seen that
Fig. 6 .6  R eactiv ity  o f anti^PCS-1 against PCS-1 and PCS 1-GC in direct ELISA
Substrate incubation was for 40min. (• ,< } )  anti-PCS-1, ( a ), anti-PCS-2, ( v )  
an ti-K L H , ( ■ ) normal rabbit serum. Each point represents the mean of 
duplicate determinations.
plate coated w ith PCS 1-GC
A ntibody dilution
plate coated with PCS-1
Moo'Soo
Antibody dilution
Fig. 6.7 R eactivity  o f anti-PCS-2 against PCS-2 and PCS2-GC in direct ELISA
Substrate incubation was for 40min. ( # , 0 ) anti-PCS-2, ( a ) anti-PCS-1,
( v )  an ti-K L H , ( ■ )  normal rabbit serum. Each point represents the mean of 
the duplicate determinations.
1.01
plate coated w ith PCS-2
0 ^ -
Antibody dilution




anti-PCS-1 was inhibited partially using peptide PCS-1 as competing antigen. The 
maximum inhibition is about 22%, while the same anti-peptide was fully inhibited by 
the extended peptide PCS 1-GC which gave 83% inhibition.
In the case of anti-PCS-2, from Fig. 6-9 it can be seen that both peptide PCS-2 
and the extended peptide PCS2-GC fully inhibited the anti-PCS-2, giving 83% and 
89% inhibitions, respectively.
6.6 INHIBITION OF ANTI-PEPTIDE SERA BY PHCS
The same technique was used in this assay as in the previous section 6.5, except 
that the anti-peptide sera (PCS-1 and PCS-2) were incubated with varying 
concentrations of native enzyme (PHCS) (0, 2, 5, 10, 20 and 50 /xg/ml) for 1 h at 
37°C, prior to transfer to wells of plate coated with 150 /d of PHCS (10 /xg/ml).
Plots of absorbance at 405 nm against the concentration of antigen (PHCS) added 
are shown in Fig. 6.10 for both anti-PCS-1 and anti-PCS-2; normal rabbit serum was 
used as control. It can be seen from Fig. 6.10, in the case of using antiT*CS-l, that 
there is a region termed "prozone" which was found in contrast to the result obtained 
with anti-PCS-2. This phenomenon might be explained by the formation of soluble 
immune-complexes. Binding of the immune-complexes to the plate could result in an 
increase in the amount of the enzyme-conjugate bound.
Fig. 6.11 shows the percentage of anti-peptide bound as a function of the 
competing antigen (PHCS) added. It can be seen that anti-PCS-1 was slightly blocked 
by PHCS and gave a maximum percentage inhibition of about 26%, but anti PCS-2 








Fig. 6 .8  Inhibition o f anti-PCS-1 by PCS-1 and PCS 1-GC in com petitive direct 
ELISA
Substrate incubation was for lh , ( • )  w ith PCS-1, (▼) w ith 
PCS 1-GC, (□ )  normal rabbit serum. Each point represents the 











Fig. 6.9 Inhibition of anti-PCS-2 by PCS-2 and PCS2-GC in com petitive direct 
ELISA
Substrate incubation was for lh , ( v )  w ith PCS2-GC, (O )  w ith PCS-2, ( □ )  




Competing antigen added (/ig/m l)
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Fig. 6.10 Inhibition of anti-peptide sera by soluble PHCS in competitive 
direct ELISA
Substrate incubation was for 45m in, ( • )  an ti- PCS-1,
( a ) anti-PCS-2, (□ ) normal rabbit serum.











Fig. 6.11 Inhibition o f anti-peptide sera by soluble PHCS 




Competing antigen added (/ig/m l)
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6.7 REACTIVITY OF ANTI-PEPTIDE SERA WITH CS FROM DIFFERENT
SPECIES
Antisera against peptides PCS-1, PCS-2 and against native PHCS were tested for 
their cross-reactivity with citrate synthase from different species. Citrate synthase from 
pig heart, E. coli and A. anitratum, the only purified CSs available, were examined 
using direct ELISA.
The plate was coated with antigen (10 /^g/ml) of different species, then each 
antigen was incubated with a range of dilutions of each antibody. The assays were 
carried out as described in section 3.7. The results obtained, plotted as absorbance at 
405nm against antibody dilution, are shown in Fig. 6.12. It can be seen that only the 
citrate synthase of pig heart reacted with the anti sera, anti4*CS-l, anti-PCS-2 and 
anti-PHCS. The citrate synthases of the other two species showed no significant 
reactivity with both anti-peptide sera, as might be expected due to the difference in 
amino acid sequence between these enzymes in the regions corresponding to peptides 
PCS-1 and PCS-2 as shown in Fig. 6.13. Anti-PHCS sera showed very slight reactivity 
with these two enzymes, possibly due to homology in amino acid sequences at other 
regions of these enzymes.
6.8 DOT-BLOT IMMUNOSTAIN
The anti peptide sera, anti PCS-1 and anti PCS-2 were tested for their reactivity 
with native PHCS using the dot-blot immunostain technique. The nitrocellulose sheets 
were cut and spotted with aliquots (2/xl) of PHCS of varying concentrations (0.1, 0.2, 
1, 10 /ig/ml in PBS) and then incubated with anti PCS-1 sera, anti PCS-2 sera 
(diluted 1/50 and 1/100) and anti PHCS sera (diluted 1/100). The experiment was 
then carried out as described in section 3.17. The nitrocellulose sheets incubated with
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Fig. 6.12 Cross-reactivity of anti-PHCS and anti-peptide sera 
w ith CS from  different species in direct ELISA 
Substrate incubation was for 45min.
Anti-PHCS ( ■ ) ,  anti-PCS-1 (O )  and an ti^ C S -2  ( a ) were reacted w ith CS 
from  pig heart (1), E. coli (2) and A. an itratum  (3). ( □ )  represents the 








Fig. 6.13: The amino acid sequence of peptides PCS-1 and PCS-2 of PHCS and the 
corresponding region of the CS sequence from E. Coli and A. anitratum
PCS-1 (288-302)
288 302
PHCS L Q K E V G K D V s D E K L R
E. Coli CS I s S - V K H - I p E F F R
A.anitratum CS I G S - V 
*





PHCS K M L  P K A K G G E  E P L P E
E. Coli CS T D S N - Y .......................................... L - E
A .anitratum CS T Q A D - Y - -  - - - - L - E
★  ★
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anti-peptide sera showed varying degrees of reactivity of the antisera corresponding to 
their dilution and the concentration of antigen, as shown in Fig. 6.14, 6.15 and 6.16. 
The nitrocellulose sheet incubated with anti PHCS showed higher reactivity than those 
incubated with anti-peptide sera, particularly at the highest concentration of antigen 
used (10 /xg/ml), as shown in Fig. 6.16. The results are summarised in Table 6.1.
6.9 IMMUNOBLOTTING OF NITROCELLULOSE-BOUND FRAGMENT OF 
PHCS
The fragmentation of PHCS by using CNBr was achieved as explained earlier in 
section 5.9b and four major fragments were produced (Fig. 5.15).
After that, electrophoretic transfer of proteins from the gel to nitrocellulose was 
achieved as described in section 3.14. Immunodetection of nitrocellulose-bound 
fragments of PHCS was performed as in section 3-16, using anti-peptide sera and 
rabbit anti-PHCS serum diluted 1/50 in 1% casein/PBS.
In this experiment, 4 gel tracks, (high molecular weight markers, low molecular 
weight markers, undigested PHCS and CNBr-fragmented PHCS, respectively) were 
stained with 0.025% (w /v) coomassie blue-R (in 7% (v /v) acetic acid) as described in 
section 3.13.
Following transfer to nitrocellulose six gel tracks were immunostained. Two tracks 
(undigested PHCS and fragmented PHCS) were incubated in separate containers with 
anti PCS-1, anti PCS-2 and anti PHCS sera.
From the graph shown earlier (Fig. 5.16), data obtained from the stained gel gave 
mol.wt. of fragments produced as 15.8K, 10K, 5.5K and 1.8K.
The reactivities of anti-sera following immunoblotting of PHCS fragments are 
shown in Fig. 6.17. A summary of these reactivities is shown in Table 6.2. The 
intensity of staining of each band in the gel, was visually rated on a scale of 1-5.
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Fig. 6.14 Dot-blot immunostain of PHCS w ith anti-PCS-1 serum diluted 1:50 (A) 
and 1:100 (B)
Each concentration in duplicate






Fig. 6.15 Dot-blot immunostain of PHCS with anti-PCS-2 serum diluted 1:50 (A) 
and 1:100 (B)
1 2  3 4
Each concentration in duplicate 





Fig. 6.16 Dot-blot im munostain o f PHCS w ith anti-PHCS serum diluted 1:100
1 2  3 4
Each concentration in duplicate 






Table 6.1 Dot-blot immunostain of anti-PHCS, anti-PHC-1 and anti-PCS-2 with native-  W .W . * .............— ----------------- -------------------------------- --------------------------- -----------*
PHCS
Spot intensity was assessed visually on scale 0-5
anti sera PHCS conc. {ng/ml)
10 1 0.2 0.1
anti PHCS (1:100) 5 4 3 3
anti PCS-1 (1:50) 3 2 1 1/2
anti PCS-1 (1:100) 2 1 1 0
anti PCS-2 (1:50) 
anti PCS-2 (1:100)
3 2 1 0
2 1 1 0
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The most intense band was assigned a value of 5 and the least intense a value of 1.
The results show that anti-PHCS detected a larger number of bands than were 
detected by anti-PCS-1 or anti-PCS-2. Anti-PCS-1 detected a band of mol.wt. 10.5K 
and additional higher mol.wt. bands. This band was not detected by anti-PCS-2, which 
detected a band of mol.wt. 8.3K and additional higher mol.wt. bands.
6.10 EFFECT OF ANTISERA ON PHCS ACTIVITY
a) Effect of antisera alone
The pure enzyme (PHCS) was diluted in 20 mM tris-H Cl/lm M  EDTA buffer, pH 
8.0, so that 10 /il aliquots would give a suitable reaction rate (0.04 units/min) in the 
assay described in section 3.18.
To investigate the effect of antisera on enzyme activity, 10 /xl samples of suitably 
diluted enzyme solution were incubated with anti sera (anti-peptide sera, anti PHCS 
sera and normal rabbit sera) at varying dilutions or with varying concentration of 
IgG’s of those sera, as described in section 3.18a.
Those antibodies that recognise and bind to epitopes within or near the active site 
should affect enzyme activity. This may be due either to the antibodies blocking the 
entry of substrates to the active site, or alternatively causing a conformational change 
"either enhancing or decreasing activity" as a result of their binding.
The results of the effect of anti-sera on the PHCS activity are shown in Fig. 6.18 
by plotting the % activity versus amounts of antisera added. From Fig. 6.18 it can be 
seen that anti-PHCS sera showed a significant effect on the enzyme activity, while anti 
PCS-1 and anti PCS-2 sera showed no significant effect.
Fig. 6-17 PHCS fragm ented at met residue by CNBr after im m unoblotting w ith an ti­
peptide serum and anti-PHCS serum
1 2 3 4 5 6
Tracks 2,4,6; undigested PHCS. Immunoblots perform ed with anti-PCS-2 (track 2), 
anti-PCS-1 (track 4), and anti-PHCS serum (track 6).
Tracks 1,3,5; CNBr-digested PHCS. Immunoblot perform ed w ith anti-PCS-2 
(track 1), anti-PCS-1 (track 3), and anti-PHCS serum (track 5).
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Table 6.2 Summary of the reactivity of anti-peptide sera and anti-PHCS serum with 
CNBr-digested PHCS
Intensity of stain band with 
Fragment Mol. Wt. (K) anti-PHCS anti-PCS-1 anti-PCS-2
a 33.8 - 1
b 33.1 1 2
c 28.8 3 1
d 25.1 2 2 1
e 20.4 3 - -
f  17.8 2 3 2
g 13.5 4 - 3
h 10.5 - 4
i 8.3 5 - 3
*j 5.5
*k 1.8
The intensity of the bands were assigned as mentioned in the text (section 6.9).






Fig. 6.18 E ffect o f anti-PHCS and anti-peptide sera on enzyme activity  before and 
after addition o f protein A-Sepharose
A ddition of ( •  ) anti-PHCS, ( a ) anti-PCS-1, (■  ) anti-PCS-2 and the open 
symbols after adding protein A-Sepharose (* )  normal rabbit serum.
100
5 0  1
Antibody dilution
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b) Effect of antisera and Protein A
As pointed out in section 3.18b, incubation of the enzyme-antibody complexes with 
protein A, followed by centrifugation, can be used to detect all antibody binding to 
the enzyme, regardless of their fine specificity. So, the assays of enzyme activity in the 
presence of a suspension of insoluble protein A were carried out as described in section 
3.18b. The results are shown in Fig. 6.18, by plotting the % activity against amounts 
of antisera added (including insoluble protein A). It can be seen from Fig. 6.18 that 
the use of anti-PHCS sera with protein A showed a greater effect on the enzyme 
activity than that without protein A. Also, both anti-peptide sera with protein A had 
an effect on the enzyme activity, whereas they did not show any significant effect 
without protein A.
6.11 DISCUSSION
From the results presented above, it can be concluded that specific antibodies 
against the synthetic peptides PCS-1 and PCS-2 were produced, when rabbits were 
immunized with peptides coupled to carrier-protein KLH. The antibody levels 
increased in the serum as the number of boosting injections was increased. Each 
antiserum reacted with the immunizing peptide, but not with the other peptide. Also, 
each antiserum reacted with either the extended or non-extended immunizing peptide 
but not with the extended form of the other peptide. However, antiTCLH sera or 
normal serum reacted with neither peptide, extended or non extended.
The reaction of anti-PCS-1 sera was partially inhibited by peptide PCS-1 
(maximum inhibition was approximately 22%), and more strongly extended peptide 
PCS1-GC (83% inhibition), when PHCS was the immobilized target antigen in 
competitive ELISA assays. Anti PCS-2 serum was strongly inhibited by peptide PCS-2
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and extended peptide PCS2-GC (83% and 89% inhibition respectively).
Anti-PCS 1 sera is only slightly blocked by intact PHCS (26%) while anti-PCS-2 
sera was inhibited by approximately 53%. We conclude that in each case part of the 
anti-peptide antibody population is directed against native determinants (blocked by 
soluble PHCS) and part of the antibody population is directed against denatured 
determinants on the solid phase antigen and can not be blocked by soluble, native 
enzyme. Anti-PCS-2 contains a greater proportion of anti-native state antibodies than 
anti-PCS-1.
When using citrate synthase from different species to detect their cross-reactivity 
with anti-peptides sera, there was no significant reactivity with E. coli "CS" and A. 
anitratum "CS"; the only reactivity was with PHCS.
This was not an unexpected result in that the amino acid sequence of pig heart CS 
shows little or no homology with E. coli or A. anitratum CS in the regions 
corresponding to peptides PCS-1 and PCS-2.
Results of immunoblot of nitrocellulose-bound CNBr-fragments of PHCS, agreed 
well with those of ELISA as both anti-peptide sera and anti-PHCS sera bind in 
varying degrees to fragments of PHCS. The intact PHCS was digested by CNBr and 
yielded four major fragments of molecular weights 15.8K, 10K, 5.5K and 1.8K, 
respectively, as discussed in section 5.9b.
From Table 5.3 (page 103), which shows the expected fragments of PHCS 
produced by treatment with CNBr, it can be seen that there is a major fragment 
between residues 267-346 of mol.wt. of 9.6K. The region corresponding to peptide 
PCS-1 (288-302) is contained in this fragment. So, the fragment of 10K mol. wt. 
yielded through digestion of the enzyme could be consistent with that fragment. The 
fragment between residues 78-127, of mol.wt. 6K, contained most the residues of PCS- 
2 (76-90), thus the fragment of 5.5 mol.wt. produced could be consistent with that 
fragment. The fragment of 15.8K mol.wt. may be as a result of partial degradation. 
Furthermore, the other observed fragment of 1.8K mol.wt., relevant to some fragments
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in the Table 5.3.
The immunoblot of native PHCS using anti-PHCS shows evidence of degradation 
of the enzyme since several lower mol.wt. bands can be seen in addition to the 
expected 49K band. A similar result is seen when anti-PCS-1 or anti-PCS-2 are used.
Table 62  shows that anti-PCS-1 and anti-PCS-2 react with predicted fragments 
(approximately mol. wt. 10K and 6K respectively) together with additional higher 
mol. wt. bands which might result from incomplete cleavage pf PHCS by CNBr. This 
is confirmed by the reactivity of anti-PHCS with fragments of mol. wt. greater than 
10K.
Anti sera to the synthetic peptides PCS-1 and PCS-2 did not show any significant 
effect on the assay of enzyme "PHCS" activity. Since both antisera were shown to bind 
intact PHCS by using the direct ELISA technique, as mentioned earlier, therefore 
binding of these antibodies to PHCS appears not to affect the activity of this enzyme. 
When the inhibition experiments were repeated with the addition of insoluble protein 
A in order to precepitate antibody-enzyme complexes, anti-PCS-1 and anti-PCS-2 were 
shown to have a significant effect on enzyme activity. This confirms that soluble 
complexes of PHCS with anti-PCS-1 or anti-PCS-2 retain their enzymic activity, and 
that this activity is lost as the complexes are precepitated with protein A.
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7.1 STRATEGY
Since the experimental study of protein antigenicity is difficult and time 
consuming, it is of considerable importance to obtain theoretical procedures for the 
prediction of protein epitopes. This is of particular interest because many protein 
sequences are obtained from gene sequences of proteins which have not been purified 
or are not available in large amounts.
So in this study a number of predictive methods were used to determine potential 
antigenic and immunogenic peptide sequences of PHCS, including methods depending 
on the amino acid sequence alone (hydrophilicity and composite surface profile) and 
methods using conformation data from the crystallographic structure of the enzyme 
(protrusion and mobility). However, it is difficult to assign antigenicity with complete 
confidence using any one parameter, although there is strong correlation between some 
of them.
According to these methods, two peptides which are thought to be important in 
the antigenic activity of PHCS were selected and synthesized, peptide PCS-1 at region 
288-302 and peptide PCS-2 at region 76-90. PCS-1 is contained in a region which 
seems to be on the external surface of the enzyme molecule, as can be seen from the 
structural model (Fig. 7.1a). It was found that both groups of predictive methods, 
those based on the amino acid sequence or the conformational structure, indicate that 
the region 288-302 could be strongly antigenic. The region containing the PCS-2 
peptide, residues 76-90, is highly predicted from a consideration of mobility (structure 
based), although this segment appears to be non-protrusive. PCS-2 is also predicted less 
reliably using sequenced-based methods. The location of PCS-2 peptide also seems to be 
on the external surface of the (PHCS) molecules as seen from the structural model 
(Fig. 7.1b), at a distance from, and not overlapping with, the PCS-1 peptide.
Fig. 7.1 Location of synthetic peptides
la) CS dimer showing monomers coloured blue and pink. The location of peptide 
PCS-1 (288-302) is indicated in yellow on each subunit.
lb) CS monomer showing the approximate location of peptides PCS-1 (288-302) 




7.2 CROSS-REACTIVITY OF POLYCLONAL AND MONOCLONAL 
ANTIBODIES TO INTACT ENZYME
Results presented in this study demonstrate that polyclonal anti-PHCS antibodies 
bind to intact PHCS as expected, and also to the two synthetic peptides PCS-1 and 
PCS-2. As indicated above, these peptides correspond to predicted epitopes of PHCS 
(regions 288-302 and 76-90, respectively). A library of MAbs, originally raised against 
PHCS, showed varying degrees of interaction with PCS-1 and PCS-2. Unexpectedly, 
most MAbs showed similar reactivity against PCS-1 and PCS-2, although these peptides 
clearly correspond to determinants which are located on different regions of the 
surface of native PHCS. However, the reactivity found between MAbs and a control 
peptide (x-peptide) suggests the possibility of non-specific interactions, which may be 
caused by conformational features of the peptides which may not correspond to their 
structures in the native molecule. Similar effects have been observed by Jemmerson 
(1987) who studied the binding of MAb to fragments of rat cytochrome C.
Clearly the use of synthetic peptides as antigens in order to identify target epitopes 
for MAbs raised against an intact, native protein may present a number of problems. 
This may relate to the probability that most native epitopes are discontinuous in native 
proteins (Barlow et al., 1986) and therefore they are not easily simulated using 
synthetic peptides.
Both anti-PHCS and MAb B showed higher binding to intact PHCS than to PCS- 
1. That may be expected in the case of anti-PHCS, since anti-PHCS serum contains 
antibodies to a number of epitopes of PHCS. The result obtained with PCS-1 suggests 
that there could be a range of conformations or an altered, conformation in free 
peptide.
Soluble PHCS inhibits anti-PHCS binding in a competitive sandwich ELISA when 
PHCS was the target antigen; in this case the PHCS is thought to exist in its native 
conformation when immobilized via the polyclonal antibody used for plate coating.
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This suggests that the majority of the antibodies in anti-PHCS serum are against the 
native conformation of the enzyme PHCS. On the other hand, it has been found that 
soluble PHCS inhibited MAb B by 16% in competitive direct ELISA when the plate 
was coated directly by PHCS as the target antigen. This result indicates that MAb B is 
directed mostly against denatured PHCS, so that binding was not inhibited by native, 
soluble PHCS. These results are consistent with the findings of Brennand (1987), who 
concluded that MAb B was probably directed against denatured PHCS from the results 
of a number of assays using both direct and sandwich ELISA techniques, when the 
target was either partially denatured or in native form.
PCS-1 showed little inhibitory effect on MAb B binding, while no effect was 
detected with PCS-2 in competitive direct ELISAs. This suggests, that these peptides 
may not represent the site of interaction of this monoclonal antibody with PHCS. This 
observation supports the suggestion by Berzofsky et al. (1982) that MAbs against 
native protein were specific for structural features present only on the native protein 
but not on any of the CNBr fragments.
7.3 CROSS-REACTIVITY OF POLYCLONAL ANTIBODIES TO SYNTHETIC 
PEPTIDES
Peptides PCS-1 and PCS-2 were synthesised in this study and antibodies against 
them were produced. Anti-peptide sera showed a strict specificity for the immunizing 
peptide (with or without extension by G C residues), and did not react with 
alternative peptide (with or without G C residues) in direct ELISA assays using 
peptide-coated plates. Both anti-peptide sera reacted with PHCS, suggesting that the 
anti-peptide antibodies produced in this study bind to PHCS preferentially at the sites 
represented by their respective homologous peptides. Similar conclusions were reached 
by Burt et al. (1986) who prepared anti-peptide sera against synthetic peptides derived
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from the sequence of rat immunoglobuline £.
Anti-PCS-1 serum was inhibited by PCS1-GC, the immunogen used in its 
production, but was only partially inhibited by PCS-1. This suggests that the majority 
of antibodies are directed against the PCS1-GC determinant. In the case of anti-PCS-2, 
it was found that both PCS-2 and PCS2-GC could inhibit the anti-serum to the same 
extent. This suggests that the majority of antibodies in anti-PCS-2 serum are directed 
against PCS-2, and do not involve the G C residues.
Having established the specifity of anti-peptide sera against synthetic peptides, 
their reactivity with fragments of PHCS was investigated. In immunoblots using 
fragments of PHCS produced by digestion with CNBr, anti-PCS-1 binds to a fragment 
of mol. wt. 10.5K, and in addition to larger fragments. The expected position of the 
PCS-1 determinant corresponds to a 9.6K fragment suggesting that the antibody may 
indeed bind to a region including 288-302 in fragments of native enzyme. Anti-PCS-2 
was observed to bind to a fragment of 8.3K and also to larger fragments. A 6K 
fragment was expected to contain the PCS-2 determinant, so it is likely that anti-PCS- 
2 binds to residues 76-90 in fragments of native enzyme. In principle, following 
complete digestion of PHCS by CNBr each anti-peptide serum should bind to a single 
fragment. In these experiments, binding to higher mol. wt. fragments is probably due 
to incomplete cleavage of PHCS by CNBr. This suggestion could be confirmed by 
producing CNBr fragments of PHCS under conditions where complete cleavage is 
obtained. It is also possible that non-specific binding of serum immunoglobulins is 
responsible for some of the observed reactivity. Immunoblots using control sera (normal 
rabbit serum and rabbit anti-KLH) should indicate which bands, if  any, are the result 
of non-specific binding.
Anti-PCS-1 was slightly blocked by soluble PHCS (in contrast to anti-PCS-2 which 
was blocked by up to 50%) in competitive, direct ELISAs with PHCS as the target 
antigen. The competitor, soluble PHCS, is in its native conformation while the target 
in this "direct" assay may be partially denatured enzyme. This suggests that most anti­
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peptide antibodies in anti-PCS-1 react better with denatured PHCS, and therefore were 
not blocked by PHCS in its native form. Anti-PCS-2 may show more reactivity with 
the native enzyme, as it was blocked by PHCS to a greater extent. This suggests that 
some anti-peptide sera may react better with native determinants, while others react 
better with denatured determinants.
When studying the enzyme activity of PHCS, both anti-peptide sera showed no 
effect on activity although the enzyme activity was inhibited by anti-PHCS polyclonal 
antibodies. Since we know from the results of competitive ELISAs that anti-PCS-2 
binds to the native enzyme, this suggests that binding of this antibody has no effect 
on the enzyme activity, while anti-PCS-1 was shown not to bind well to native 
enzyme. When staphylococcus aureus protein A was used to precipitate all enzyme- 
antibody complexes, an increased effect of anti-PCS-1 and anti-PCS-2 was seen. Under 
these conditions, anti-PHCS caused complete loss of activity from the solution.
Cross-reactivity of anti-PCS-1 and anti-PCS-2 with CS from different species (pig,
E. coli and A. anitratum showed that the only binding was to CS of pig heart. 
Comparison of the alignments of CS sequences from these species suggests that this is 
the expected result, since there are major differences in amino acid sequence between 
these enzymes in the regions corresponding to peptides PCS-1 and PCS-2 (Fig. 6.13). 
On the other hand, this comparison suggests that yeast CS, and perhaps other 
eukaryotic CS, may bind these anti-peptide antibodies, due to the homology of these 
peptides with yeast CS as shown in Fig. 12. Pullen et al. (1985) showed that rabbit 
anti-serum to pig CS was cross-reactive with the enzyme from pigeon and, to a less 
extent, with that from Bacillus megaterium and E. coli. This indicates that there are 
other antigenic regions of the CS molecule which are more closely related between 
species than PCS-1 or PCS-2 peptides.
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7.4 CONCLUSIONS
Synthetic peptides are extensively used in the field of immunology, hormone- 
receptor interactions and vaccine research. The general approach is to synthesize 
peptide homologs or analogs of segments of a larger polypetide or protein and evaluate 
their immunochemical characteristics. Because there have been limitations on the 
number of peptides which could be readily synthesized and tested, the choice of 
peptides has often been made on the basis of predictive algorithms which have 
appeared in the scientific literature in recent years (e.g. Thornton et al., 1986; Westhof 
et al., 1984; Hopp and Woods, 1981). When anti-sera are produced against synthetic 
peptides, a major objective is to obtain anti-sera which will react with the 
corresponding protein in its native state.
As pointed out earlier, methods used to predict protein epitopes can be divided 
into two main categories; those depending on the amino acid sequence and those 
depending on the conformational structure of the protein. So, when the amino acid 
sequence of a protein is available, it is sometimes possible to predict its epitopes by 
using the parameters based on the sequence.
It can be seen in the literature how the antigenic regions of simple proteins have 
been identified when their amino acid sequences are known (e.g. swMb; lysozyme, 
myohaemrythrin and TMVP). But the prediction of these epitopes will be more 
accurate if  the conformational structure of the protein is available and the predicted 
regions agree with those identified from the amino acid sequence.
Although the prediction of the three-dimensional structure of a protein from its 
amino acid sequence remains one of the fundamental unsolved problems in molecular 
biology (Thornton, 1988), there is much information available for the structure and 
function of the model protein (PHCS) used in this study. Therefore, it has been 
possible to use both groups of predictive methods to identify which regions of PHCS 
are important in antigenic activity. In the case of PHCS, epitope prediction methods
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based on sequence data suggested peptide antigens which were shown to produce anti 
sera capable of reacting with the native protein. Conformation-based methods generally 
confirmed these predictions.
Consequently, it can be concluded that these predictive approaches are potentially 
useful for the many protein sequences available, many of which are obtained from the 
gene sequences. Furthermore, conformational data of proteins, which are much more 
difficult to obtain and hence not usually available, may not be essential for epitope 
prediction. On occasions, the protein itself may not have been purified and 
characterised, making such data impossible to obtain.
Antisera raised against synthetic peptides (selected on the basis of various 
predictive methods) showed specificity for the immunizing peptide and cross-reactivity 
with the corresponding determinant in the intact protein. On the other hand, this work 
has produced no clear evidence that antisera or monoclonal antibodies against the 
intact enzyme are directed against those continuous determinants which are identified 
by epitope prediction methods. It is likely that anti-protein antibodies are directed 
against discontinuous epitopes which cannot be predicted by the methods used nor 
simulated by synthetic peptides corresponding to short segments of the linear amino 
acid sequence.
The work reported in this study suggests that the use of epitope prediction 
methods to identify potential synthetic peptide immunogens can be extended to the case 
of oligomeric proteins.
7.5 SUGGESTIONS FOR FURTHER WORK
1. It would be interesting to select and synthesise other peptides which are from a 
region not thought to be antigenic in the native CS molecule, and to produce anti-sera 
against these peptides. Such peptides could be selected from the interface region
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between the two subunits of the dimer PHCS, or from regions which are buried within 
the monomeric subunit in its native conformation. The reactivity of these anti-peptide 
sera could be examined with native protein, protein fragments and other peptides to see 
whether they also will react with the native or denatured protein.
The results of these experiments would provide an additional test of the validity of 
the predictive methods and to investigate the relevance of this approach in the study 
of oligomeric proteins.
2. The research group is interested in a number of problems related to CS from a 
range of eukaryotic and prokaryotic species. One project is attempting to construct a 
3D-structure for the hexameric CS from E. coli by computer homology modelling from 
its amino acid sequence with respect to the sequence and crystal structure of the 
dimeric PHCS. A dimer of the E. coli CS has been modelled so far and the assembly 
of three dimers into a hexamer is now being considered. It would be interesting to 
select peptides from the surface of this modelled dimer and to raise antibodies to them; 
cross-reactivity of these anti-peptide sera with the native, hexameric E. coli CS may 
then give clues as to which parts of the dimer are still exposed after association into 
the hexamers and which parts are buried.
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